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CHAPTER I 
 
 
INTRODUCTION 
 
Cholesterol (CL) plays a variety of important roles in maintaining cellular functions.  CL 
is required by all animal cells for cell membrane structure and signaling. Cells obtain this 
CL either through intracellular synthesis or through receptor-mediated endocytosis of 
extracellular CL (associated with lipoproteins).  Despite the ability to readily obtain CL 
from synthesis and uptake, most cells have only a limited ability to catabolize CL [1].  
Homeostasis is maintained through the cell-specific balance of synthesis, uptake, limited 
catabolism and efflux.   
However the means of accumulation, CL homeostasis of cells must be maintained, 
mainly through the process of CL removal termed reverse cholesterol transport (RCT).  
RCT involves the generation of high density lipoprotein (HDL) from apolipoprotein 
(mainly apoA-I) uptake of cellular lipids, including phospholipid (PL) and CL.  Because 
the process of CL delivery to non-liver cells (commonly referred to as peripheral cells 
when speaking on cholesterol transport) via low density lipoprotein (LDL) was described 
as ‘cholesterol transport’, the process of CL removal and transport back to the liver was 
understandably termed reverse cholesterol transport [2].  Importantly, RCT from 
macrophages is theorized to be atheroprotective since CL-loaded macrophages are a 
causative component of atherosclerotic lesions. 
Lipoproteins move throughout circulation and are remodeled based on metabolic states.  
HDL receives CL from cells and delivers it via different routes for eventual transport to 
the liver where it is processed and excreted as bile salts or recycled in order to maintain 
CL homeostasis [3].   
Despite the fact that the majority of HDL is initially formed from the liver, contribution 
from other cell types cannot be discounted since HDL is dynamically remodeled (see 
chapter II) and lipid free apoA-I is constantly released from lipoparticles.  As HDL 
circulates in plasma, several enzymes participate in the remodeling of HDL components
 2 
 
for the purposes of acylation and movement of cholesterol, transferring phospholipids, 
movement of triglycerides for lipolysis and importantly releasing lipid-poor/lipid-free apoA-I 
[4].  This release provides cells with substrates needed to form HDL (cellular lipids and 
apolipoprotein).  In light of this, various tissues have the potential to contribute to HDL 
compositions in circulation regardless of the initial source of the lipoparticle. It is also 
apparent that characterization of this process from different, contributing cell types is crucial 
to a complete understanding of HDL regulation. 
The initial step in HDL biogenesis involves the binding of lipoproteins (i.e. apoA-I) to the 
cell surface and the membrane transporter ATP-binding cassette transporter A1 (ABCA1). 
This is believed to stimulate lipid (mainly CL and PL) efflux.  Although the entire RCT 
pathway is needed for efficient removal of cellular CL, the initial steps are thought to be 
crucial as evidenced by the lack of this process in Tangier’s disease (TD) [5-9].  TD patients 
have significantly lower HDL levels and high cellular cholesterol ester accumulation [10].  
Mutations in ABCA1 have been shown to be the cause of TD [11-13].  The ABCA1 role in 
HDL biogenesis is seen in the inability of cells from TD patients to efflux lipids to apoA-I 
[14, 15].    Since the discovery of ABCA1 as a possible lipid transporter, extensive research 
has been done in macrophage and liver cells identifying transporters involved in lipid efflux 
to apoA-I or HDL acceptors, however characterization of the process in other cell types is 
lacking [16-20]. 
ApoA-I is the major protein component of HDL and is involved in HDL formation and 
cholesterol removal [18].  ApoA-I-mediated HDL biogenesis is dependent on the levels and 
activity of the membrane protein ABCA1 [21, 22].  Initiation of lipid efflux (CL and PL) to 
apoA-I involves binding of apolipoprotein to ABCA1 on the cell membrane [8, 9].  But the 
mechanism and order of CL/PL lipidation or if this process also involves apolipoprotein 
internalization for access to intracellular stores of lipids, is unknown.   
Adipose tissue is the largest storage site of free cholesterol and functions as a metabolic 
regulator in the body.  For these reasons, the adipocyte role in HDL formation and the 
mechanism of such must be investigated in order to understand how overall HDL levels and 
lipid compositions can be influenced by adipose tissue.  These studies contribute to this 
question by characterizing the role and contribution of adipocytes to apoA-I-dependent lipid 
efflux.  Although adipocytes have been shown to efflux cholesterol to apoA-I, 
characterization of this process is not complete [23, 24].   
The mechanism of apoA-I lipidation by adipocytes also needs further investigation.  The 
transporter ABCA1 is suspected to be involved in lipid efflux to apoA-I but direct evidence 
is lacking.  Controversially, apoA-I has also been proposed to enter cells for partial lipidation 
[25, 26].  Because adipocytes store free CL in their cytosolic lipid droplets (LD), a process 
involving apoA-I internalization to access these stores is attractive.  Previous studies by this 
laboratory have shown that activation of lipolysis in adipocytes leads to a 22% enhancement 
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in CL efflux to HDL despite lowered levels of plasma CL in the lipolytic state [27, 28].  This 
implicates a need for transport from intracellular CL stores.  Furthermore, the addition of 
brefeldin A (BFA), a drug known to interfere with Golgi/ER structure and block vesicular 
transport as well as ABCA1-mediated CL efflux [29-31], abolished the lipolytic 
enhancement of CL efflux [27, 28].  This seems to indicate that efflux in adipocytes involves 
mobilization of intracellular CL stores through BFA-sensitive vesicular transport.  These 
findings have led us to investigate the role of apoA-I internalization in HDL biogenesis from 
adipocytes.  
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
 
i. Lipid Transport 
Lipids are transported throughout the body to maintain energy levels and lipid 
homeostasis.  These lipids are solubilized with the help of apolipoproteins that bind to the 
surface of the lipids and can also participate as co-factors of metabolizing enzymes.  The 
resulting lipoprotein particles are classified based on their densities, which is reflected in 
their naming.  High, low and very low density lipoproteins (HDL, LDL, VLDL) carry 
lipids to and from cells based on their specializations.  Generally, VLDL and LDL 
transport triglycerides (TG) and CL to peripheral cells and HDL transports CL from 
peripheral cells back to the liver.  VLDL and LDL are known to be atherogenic while 
HDL is anti-atherogenic [32-34].   
HDL can be spherical or disc-shaped depending on its lipid load.  Discodial HDL is 
mainly composed of PL, lipoproteins (mainly apoA-I) and little to no CL.  The PL stack 
as in a truncated bilayer and apolipoproteins wrap around the exposed hydrophobic tails 
of the PL like a belt [35].  Spherical HDL is composed of a monolayer of PL containing 
lipoproteins and enzymes, with a neutral core of lipids.  As described below, HDL can be 
further divided into distinct classes based on characteristics such as density, charge and 
size.  Studies have shown these different types of HDL to be different in their 
functionality and relationship to atherosclerosis risk.  
 
ii. Classifications of HDL 
The traditional way to separate and purify different classes of lipoproteins is by 
ultracentrifugation [33].  The particles separate based on hydrated density as reflected in
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their nomenclature [36].  HDL is separated from other serum lipoproteins at 
d>1.063 g/mL and can be subclassified by further centrifugation into (HDL2 or HDL3) 
based on the amount of lipid (density) in the lipoprotein.  HDL3 is the smaller, denser 
lipoparticle that can be either disc-shaped or small spherical (1.21>d>1.125 g/mL) 
containing mainly apoA-I and PL but can also contain small amounts of CL and other 
lipoproteins (such as apoA-II).  HDL2 is larger, spherical and less dense 
(1.125>d>1.063 g/mL) and contains lipoproteins (mainly apoA-I), PL, TG, CL and 
cholesteryl esters.  
Other methods of separation have also resulted in different nomenclature of HDL.  HDL 
can be separated by its surface charge using electrophoretic mobility into pre-β-migrating 
or α-migrating HDL [37].  Pre-β HDL includes both lipid-free/lipid-poor apolipoproteins 
and discodial HDL.  α-Migrating HDL includes spherical lipid loaded HDL as well as 
some discodial HDL (see table 1).  
 
Table 1. HDL Classifications 
Shape of 
particle 
apoA-I 
Protein 
component 
Lipid 
component 
Electrophoretic 
Mobility 
Subfraction 
Density 
(g/mL) 
Particle Size 
(nm) 
lipid free/lipid 
poor apoA-I 
apoA-I 
single molecule 
little-no 
phospholipid pre-β 
       HDL 3c     
       d~1.171     7.2-7.8 
discodial HDL 2-3 apoA-I 
mainly 
phospholipid 
(small amounts  
of CL) 
pre-β  
 
HDL 3b  
d~1.154 7.8-8.2 
   
 
 
HDL 3a  
d~1.136 
    8.2-8.8 
 
spherical HDL 2-4 apoA-I phospholipid, CL, CE and TG αlpha 
 
 
HDL 2a  
d~1.115     8.8-9.7 
    
 
 
HDL 2b  
d~1.085     8.7-12 
 
 
iii. Sources of HDL and apoA-I 
ApoA-I can be synthesized and secreted from the liver or intestine [38-40].  Some studies 
have estimated that apoA-I is mainly found in the lipid bound form with only ~3-8% (of 
total apoA-I) in the lipid-free/lipid-poor form [41].  ApoA-I is stabilized by binding to 
lipids and lipid-free apoA-I is rapidly removed from circulation by catabolism in the 
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kidney [42].  ApoA-I collects PL and CL from cells (or possibly from lipoproteins) to 
form HDL (Fig. 1) [43, 44].  The main sources of nascent HDL are the liver and intestine.  
In studies, circulating levels of HDL were reduced by ~80% when the transporter 
ABCA1 was tissue-specifically knocked out of mouse liver cells [42].  Similar 
experiments with intestinal ABCA1 knockouts revealed an additional ~30% released 
from the intestine [45].  Although this implies that the liver and intestine have a large 
influence on HDL compositions and levels, the potential contributions to HDL biogenesis 
of other tissues cannot be ignored since lipoproteins are dynamically remodeled in 
circulation and apoA-I constantly released. 
 
Figure 1.  HDL Biogenesis.  Apolipoproteins (mainly apoA-I) interact with the cell surface resulting in 
lipoprotein lipidation by phospholipids (PL) and cholesterol (CL).  These nascent lipoparticles form a 
discodial structure which composes the highest density of HDL fractions.  The surface contains the enzyme 
lecithin:cholesterol acyltransferase (LCAT) which converts CL to cholesterol esters (CE).  The CE are 
more hydrophobic than CL and are relocated internal to the surface lipids-forming spherical HDL.    
 
iv. Lipoprotein remodeling and apoA-I release 
HDL is remodeled by plasma factors primarily located on the surface of the lipoprotein 
particle.  Remodeling results in transfer of lipids and release of lipid-free/lipid-poor 
apoA-I from HDL.  CL is deposited into HDL as free cholesterol and converted into 
cholesteryl esters by lecithin:cholesterol acyltransferase (LCAT) [2].  Cholesteryl esters, 
which are more hydrophobic than CL, are then relocated into the center of the HDL 
particle resulting in a conversion from disc-shaped to spherical HDL [46].  HDL becomes 
larger and less dense as it collects more lipids, either through active flux or diffusion 
from cell surfaces, and the collected CL is converted to cholesteryl esters by LCAT.   
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Release of apoA-I occurs in different ways but can be grouped by two general themes.  
Either enzymes have remodeled HDL into too large of a particle which is unstable and 
releases apoA-I to downsize and stabilize the structure or enzymes have decreased the 
size of the lipoparticle and less apoA-I is needed.  For instance, as LCAT converts CL to 
cholesteryl esters, the HDL particle becomes larger and acquires more apoA-I particles 
[46-48].  This larger HDL, which contains four apoA-I particles is less stable and can 
release lipid-poor apoA-I to become more stable.  Cholesterol ester transfer protein 
(CETP) is another enzyme that facilitates HDL remodeling by moving cholesteryl esters 
from HDL to apoB-containing lipoproteins such as VLDL.  This activity is accompanied 
by movement of TG from the other lipoproteins back to HDL [49].  CETP helps generate 
lipid-poor/lipid-free apoA-I in three different ways.  One way is through the 
TG-enrichment of HDL which becomes the preferred substrate of hepatic lipase (HL) [4, 
50].  Hydrolysis of TG by HL results in release of non-esterified fatty acids and 
remodeling of HDL.  The remodeling of HDL into smaller particles results in the release 
of lipid-poor/lipid-free apoA-I [51, 52].  Secondly, TG-rich HDL is also the preferred 
substrate of phospholipid transfer protein (PLTP).  PLTP activity has been implicated to 
cause a fusion of lipoparticles which produce a larger, unstable HDL and subsequentially 
release apoA-I in order to stabilize the particle [53, 54].  Thirdly, CETP promotes the 
release of apoA-I related to the rate of TG transfer from VLDL.  Because this rate is 
lower than the rate of VLDL catabolism, less net TG may be transferred back to HDL.  
This results in a lipid-depleted, smaller HDL particle which also releases 
lipid-poor/lipid-free apoA-I [55].     
ApoA-I is also released from chylomicrons during lipoprotein lipase (LPL) hydrolysis of 
TG [56].  Studies show that radiolabeled chylomicrons release apoA-I for uptake mainly 
to the HDL fraction after injection into the lymph [57, 58].  This constant remodeling and 
release of apoA-I provides substrate (apoA-I) for other tissues, besides liver and intestine, 
to participate in HDL biogenesis (Fig. 2).  Despite this, few studies have sought to 
characterize these processes. 
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Figure 2.  HDL Remodeling and ApoA-I release.  HDL is metabolized in circulation resulting in lipid 
transfers, size changes and lipoprotein release.  Diagrammed above are remodeling pathways which may 
lead to lipid-free/lipid-poor apoA-I release from lipoparticles.  Lecithin:cholesterol acyltransferase (LCAT) 
has been shown to result in lipoparticle fusion which releases apoA-I to help stabilize the resulting large 
and unstable HDL.  Cholesterol ester transfer protein (CETP) activity yields triglyceride (TG)-enriched 
HDL as well as lipid depleted HDL when TG transfer is incomplete. TG-enriched HDL is a favored 
substrate for both hepatic lipase (HL) and phospholipid transfer protein (PLTP).  HL hydrolyzes the TG 
and decreases the size of the HDL which releases apoA-I.  PLTP has been shown in vitro to cause particle 
fusion resulting in large and small HDL products with release of apoA-I.  
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v. Importance of studies on lipid efflux from adipocytes 
As mentioned above, efflux from the liver and intestine contribute the majority of initial 
circulating HDL in mice but these studies failed to account for the metabolic potential of 
adipocytes for influence on these levels [42, 45].  Adipocytes compose the largest 
reservoir of stored free CL in the body [59, 60].  The mass of the stored CL is 
proportional to the amount of adipose tissue and TG and in the case of obesity can 
account for over half of the body’s stored CL [61, 62].  Lipolytic mobilization of fat 
stores has been shown to increase CL efflux to recombinant HDL particles [27].  Studies 
have also shown correlations in obesity and altered component lipid ratios of circulating 
HDL [63-65].  Furthermore, accumulation of upper body fat is associated with decreased 
HDL-CL levels and increased cardiovascular heart disease (CHD) risk [64].  This 
suggests that overall HDL levels and particle compositions may be greatly affected by 
lipid efflux from adipocytes.  Although apoA-I has been demonstrated to interact with 
and stimulate lipid efflux from other cell types, the process has not been well 
characterized in adipocytes.  Thus, adipocytes have an unknown potential to influence 
HDL composition and CL levels.   
 
vi. Not Just Concentration: Importance of HDL function  
HDL composition may be an important characteristic affecting functionality.  Literature 
has linked the CL and PL composition of HDL to its downstream efflux potential [66-
73].  In light of this, the lipid compositions of circulating HDL may play a more 
atheroprotective role than the overall HDL levels.  Several studies have characterized the 
PL to CL ratios of apoA-I-dependent lipid efflux from cells such as: macrophages, 
fibroblasts, smooth muscle cells, erythrocytes and TD fibroblasts [16-20].  The HDL 
particles formed were shown to vary in composition from CL-rich to CL-poor and for the 
case of the latter two, no detectable HDL was formed.   
Because CL can efflux to HDL via several different pathways, it is reasonable to predict 
that different HDL subclasses may vary in their success as acceptors.  The different 
mechanisms for efflux from the cell to HDL acceptors involve 1) ABCA1-mediated 
efflux to apolipoprotein (i.e. apoA-I) acceptors; 2) scavenger receptor BI 
(SRBI)-mediated flux to HDL; 3) ABCG1-mediated efflux to HDL and 4) passive 
diffusion to HDL.  Studies on the mechanisms, substrate affinities, activities and relative 
contributions of these pathways have been performed predominately in macrophages.   
SRBI is found in many cell types [74-76] and mediates flux of CL to and CE from HDL 
[76, 77].  The relative contribution of SRBI to CL efflux from macrophages (compared to 
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the other pathways) seems to be minor compared to ABC A1 and G1 [78-80].  ABCG1 
has recently been identified for its ability to efflux CL out of the cell similar to ABCA1 
but prefers HDL as an acceptor rather than lipid-free apoA-I [69, 81, 82].  Some studies 
have predicted that ABCG1 contributes ~20% of overall cellular CL efflux from CL-
loaded macrophages [80] but its role in other cell types remains largely uninvestigated.   
ABCA1 mediates the efflux of both PL and CL to apolipoprotein acceptors [83-85].  Its 
ability to efflux to HDL as an acceptor is greatly diminished compared to apolipoprotein 
acceptors [86].  ABCA1 is thought to be essential for the maintenance of HDL levels in 
circulation as evidenced by extremely low HDL levels in TD patients and ABCA1 
knockout mice [10, 42, 45, 87].  Passive diffusion of CL to HDL has been proposed to be 
significant when the HDL acceptor surface is CL-poor compared to the plasma surface of 
the cell.  This process is believed to be dominant when the cell contains low 
concentrations of active CL transporters such as ABCA1 and G1 [80, 88].   
 
vii. HDL compositions and disease 
Cardiovascular disease is the leading cause of death in developed countries, accounting 
for ~30% of deaths [89].  Seminal epidemiological studies have shown an inverse 
relationship between HDL concentration and the risk of CHD [32, 90-93].  Because of 
this, plasma HDL concentration levels have become a common component of 
atherosclerotic risk assessment.  More recently however, the results from studies seem to 
suggest that HDL levels alone may not be the determining factor in atherosclerotic risk.  
Studies have suggested that CHD risk may be inversely related to HDL particle size [63, 
94, 95].  In agreement with this, cross-sectional studies have shown HDL3 to correlate 
with higher TG levels, apoB (the main protein component of LDL and VLDL), VLDL 
mass and overall lower HDL concentrations [96].  Also, studies on patients that had 
recently survived heart attacks found a higher percentage of HDL3 in these patients 
compared with controls and found that all patients studied had an inverse relationship of 
HDL2 to HDL3 concentrations [97].  Other studies have found that HDL2 correlates with 
lower CHD risk factors [63, 94].   
On the other hand, some studies have implicated the protein content of HDL to influence 
its atheroprotectiveness.  Mice transgenic for either human apoA-I or apoA-I/apoA-II 
showed atherosclerotic lesions to be 15-fold higher in apoA-I/apoA-II mice [98]. This 
suggests that the protein component of HDL may also influence its ability to promote 
lipid efflux from macrophage foam cells.  
Studies have also shown that HDL function within the RCT pathway directly affects its 
ability to be atheroprotective.  A small study of CHD patients showed that patient serum 
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efflux capacity correlated to coronary events.  This led the authors to speculate that the 
defective serum was indicative of a defective ABCA1 efflux pathway [99].   
There are also studies which break the “high HDL, lowered risk” rule.  An example of 
this are studies showing increased atherosclerosis despite increases in HDL levels, 
presumably because HDL function in the RCT pathway was impaired [100-102].  In the 
Honolulu Heart Program Cohort study, a genetic CETP deficiency produced increased 
CHD in subjects despite increased or unaffected HDL concentrations and increases in 
HDL size [102].  The authors proposed this unusual correlation to be due to decrease in 
functionality of the RCT pathway since CETP deficiency has been linked to lower LCAT 
activity levels.  Similarly, clinical trials of the CETP inhibitor torcetrapib showed 
increased HDL levels as well as increased cardiovascular events and mortality.  It is not 
known if this was due to decreased function of the larger HDL products of CETP 
inhibition or if it was due to the off-target effects of the drug [101].    
Conversely there are examples in which decreased HDL does not lead to an increased 
CHD risk.  For instance, apoA-IMilano is a mutant form of apoA-I found in an Italian 
family exhibiting lower levels of HDL as well as a decreased risk of CHD [103].  This 
was later determined to be due to the apoA-I mutation which results in a more efficient 
apoA-I CL acceptor than wt apoA-I [104].  Similar to this is the apoA-IPARIS mutation 
which results in dramatically lower HDL without increased evidence of CHD [105, 106].  
Other genetic mutations that can cause lowered HDL levels include LCAT deficiency, 
which also does not result in enhanced CHD (except in compound cases) [107, 108].  
Due to these findings it is evident that HDL levels alone cannot be the sole determining 
risk factor and risk assessment should be extended to include HDL functionality within 
the RCT pathway.  
Thus, since HDL compositions affect functionality and HDL is constantly in flux, then 
the compositions and classes present in circulation are most likely reflective of tissue 
energy levels and metabolic needs.  This means that although extensive studies in 
macrophages are warrented due to the direct atheroprotectiveness of CL efflux out of 
foam cells, studies in other tissues are just as important to determine the type of HDL in 
circulation that would reach macrophages and other peripheral cells. 
 
viii. Mechanisms of nascent HDL formation 
HDL is formed when apoA-I interacts with the cell surface to facilitate removal of 
cellular lipids.  RCT is dependent on HDL to circulate and retrieve CL from overloaded 
cells.  This process is very important as evidenced by the negative correlation of HDL 
levels and the risk for cardiovascular disease [32].  The most vital component to this 
entire process seems to be the very beginning steps involving HDL biogenesis.  Without 
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the ability to create HDL and remove CL, cellular CL homeostasis can become 
imbalanced.  Lowered apoA-I/HDL levels and/or functionality translates to a reduced 
ability to remove cellular CL.   
In 1961, patients were identified who exhibited hepatosplenomegaly, severely enlarged 
lymph nodes and dramatically lower levels of HDL [10].  It was first speculated that this 
was some type of Niemann-Pick C (NPC) disease which is a lipid storage disorder known 
to cause lipid droplet accumulations.  But unlike NPC disease, these patients showed no 
eminent signs of central nervous system degeneration.  The patients, who were siblings, 
were residents of an isolated island off the coast of Virginia called Tangier’s Island.  
Thus this lipid storage disorder was labeled as Tangier’s disease (TD) (for review see 
[109]).  In 1999, several labs identified the missing essential component of efflux in TD 
patients to be caused by mutations in the gene coding for the ABCA1 [11-13].  ABCA1 
role in HDL biogenesis can be seen in the inability of TD fibroblasts to efflux lipids to 
apoA-I [14, 15].  Thus ABCA1 emerged as the transporter most likely responsible for 
lipidation of apolipoproteins and HDL biogenesis [5-9].   
Since this discovery ABCA1 has been extensively studied and ABCA1 is known to 
mediate the efflux of lipids to apolipoprotein acceptors [43].  However, questions related 
to the mechanism of lipidation remain.  Some have proposed that CL efflux occurs 
simultaneous to PL efflux and others that it is subsequential and independent from the PL 
loading of apoA-I [5, 7, 110-112].  Also, there are controversies over the apoA-I location 
of lipid uptake.  ApoA-I lipidation has been proposed to occur on the surface of the 
plasma membrane by the binding of apoA-I to lipid perturbations caused by ABCA1 and 
solubilization of the lipids into HDL particles [7, 113, 114].  Alternatively, some studies 
have proposed that lipidation involves the recycling or “retroendocytosis” (i.e. 
endocytosis followed by exocytosis) of apoA-I as evidenced by colocalization studies 
with ABCA1 or by monitoring radiolabeled apoA-I release or by cell-surface 
biotinylation studies [115-120].  Although these studies utilize methods that show apoA-I 
endocytosis there is disagreement on the level of contribution that this pathway has 
towards HDL formation.  Variation in the proposed functions of apoA-I recycling most 
likely result from the differences in the methodologies used.  Further, many of the 
methods suffer from an inability to distinguish internalized protein from membrane 
bound protein and inherent problems due to label exchange and degradation.   
A method of labeling developed by this laboratory and employed in these studies, clearly 
distinguishes internalized and re-secreted protein from cell surface bound protein by 
using a recombinant apoA-I containing a protein kinase A (PKA) recognition tag (pka-
apoA-I) [28, 121].  This construct can be used to ask the question: is apoA-I lipidated 
with PL and CL from the surface of adipocytes or is the retroendocytosis of apoA-I 
required for intracellular lipidation or to initiate unknown signaling pathways?  Because 
adipocytes store free CL in their cytosolic lipid droplets (LD), a process involving apoA-I 
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internalization to access these stores seems plausible.  Also, previous studies have 
implied that efflux in adipocytes involves mobilization of intracellular CL stores through 
BFA-sensitive vesicular transport [27, 28].    
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CHAPTER III 
 
 
MATERIALS AND METHODS 
 
i. Materials.   
J774 and 3T3 L-1 cells were purchased from American Type Cell Culture (Manassas, 
VA).  Isoproterenol, dimethyl sulfoxide (DMSO), brefeldin A, glyburide, fatty acid free 
bovine serum albumin (BSA), isobutyl methyl xanthine (IBMX), dexamethasone, trypsin, 
insulin, 8-Br-cAMP, GW3965, secondary antibody (anti-rabbit) perioxidase conjugated, 
streptomycin and penicillin were purchased from Sigma Chemicals Co. (St. Louis, MO).  
Fetal bovine serum (FBS) was obtained from Hyclone (Logan, UT).  Dulbecco’s 
modified Eagle’s medium (DMEM) was purchased from Cellgro Mediatech, Inc 
(Herndon, VA).  Block lipid transport-4 (BLT4) was received from Chembridge Corp. 
(San Diego, CA).  BLT1 was a gift from Dr. George H. Rothblat.  Polyclonal 
anti-ABCA1 NB400-105 and monoclonal antibodies to the β subunit of ATP synthase 
clone “3E8” NB600 were purchased from Novus biological (Littleton, CO).  Antibody to 
ATP synthase β clone “3D5” was purchased from Abcam ab14730 (Cambridge, MA).  
Chemiluminiscence kit and Hybond ECL nitrocellulose membrane for Western blotting 
was obtained from Amersham Biosciences (Piscataway, NJ).  Film for autoradiography 
and western blotting was Fuji RX Film (Greenwood, SC).  Infinity Cholesterol Reagent 
was purchased from Hitachi (Indianapolis, IN).  Phospholipid C kit was purchased from 
WAKO diagnostics (Richmond, VA).  Infinity Triglycerides Reagent was purchased 
from Thermo (Louisville, CO).  Plasmid pET30 EK/LIC was obtained from Novagen 
(Gibbstown, NJ).  [32P]-H3PO4 in H2O was from MP Biomedicals (Irvine, CA).  
[3H]-choline and [3H]-cholesterol was purchased from PerkinElmer (Waltham, MA).  Ni-
sepharose resin was purchased from Amersham (Piscataway, NJ).  Densitometric analysis 
was done with AlphaEase Software (Santa Clara, CO).  Graphs and statistical 
calculations were performed using GraphPad (La Jolla, CA).  
 
 15 
 
ii. Cell culture.   
J774 macrophages or 3T3 L-1 pre-adipocytes were cultured at 37⁰C in 8% CO2 
atmosphere in DMEM supplemented with 10% FBS and 0.01% antibiotics.  J774 were 
allowed to reach 90% confluency prior to experiments.  For differentiation of 3T3 L-1 
into adipocytes, cells were allowed to grow to confluence then the differentiation into 
adipocytes was induced by addition of IBMX (111 µg/mL), dexamethasone (0.46 µg/ml), 
and insulin (1.5 µg/ml) [122].  After 48 h, the cells were incubated in DMEM/10% FBS 
containing insulin for an additional 48 h.  Afterwards the cells were maintained in 
DMEM/10% FBS.  All experiments using adipocytes were conducted 12-14 days after 
the differentiation period. 
 
iii. Analysis of whole well adipocyte or macrophage cell homogenates.   
Cell monolayers from individual 6-well plates containing 14-day old fully differentiated 
3T3 L-1 adipocytes or confluent J774 macrophages were scrapped and homogenized.   
Total well concentrations of protein were determined by dilution of homogenate in 
10% SDS and the absorbance was measured to obtain the second derivative of 
Anm=281(max) minus the second derivative of Anm=291(min).  This allows removal of the 
disturbance due to DNA abosorbance at Anm=260 in the homogenate.  The concentration 
was then calculated using ε“=0.017 to determine the cellular protein.   
Next, aliquots of homogenate were used for lipid extraction with chloroform:methanol 
(2:1 by vol) by the Folch method [123].  Organic phase lipids were then separated by 
TLC (along with standards) and iodine used to visualize cholesterol (CL) or 
phospholipids (PL).  The spots of both samples and standards were then cut from the 
plates and lipids extracted from the silica with either 1:1 chloroform:methanol (CL) or 
80:20 methanol:chloroform (PL) and dryed.  These lipid extracts were then reconstituted 
as per manufacturer instructions for either a choline-containing phospholipid colorimetric 
assay (Phospholipid C assay kit, WAKO) or a cholesterol colorimetric assay (Infinity 
Reagent, Hitachi).   
Once well lipid content was determined, the moles of lipids in homogenates were then 
divided by protein concentration per well in order to standardize each well by protein 
content.  For apoA-I dependent lipid efflux quantification, the sample % efflux value 
(calculated in Efflux Assays below) was multiplied by the total cellular lipid content per 
mg homogenate protein.  This gives the nmol CL or PC / h • mg cellular protein. 
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iv. Cholesterol efflux Assays.   
Fully differentiated 3T3 L-1 adipocytes or J774 macrophages were labeled with 
[3H]-cholesterol (2 µCi/mL with 44.5Ci/mmol) 22-24 h prior to experiment in the 
presence of 2 µM GW3965 (or buffer) for adipocytes or 180 µM 8-Br-cAMP (or buffer) 
for macrophages in 2.5% FBS-DMEM.  Previously reports from our laboratory have 
shown that labeling of adipocytes for 24hrs with [3H]-cholesterol results in a final 
distribution of labeling to 96% cholesterol and 4% cholesterol esters [44].  Recombinant 
apoA-I cloned and purified as previously described was used to initiate cellular lipid 
efflux [121].  At the start of the experiment fresh 0.05% BSA-DMEM was added to the 
cells with 75 µg/mL apoA-I (or with buffer to determine background levels of efflux).  
Aliquots of media were taken at indicated time points, briefly centrifuged and 
[3H]-cholesterol efflux determined by scintillation counting.  After allowing efflux to 
proceed for 5 h the wells were washed and the cholesterol extracted into isopropanol for 
counting.  Whole well [3H]-cholesterol (cpm) was determined by adding the cpm found 
in the media to the cpm present in the isopropanol extract.   The % of cellular CL efflux 
was calculated at each time point as: 
% of CL efflux = cpm media*100/(cpm media + cpm homogenate).   
ApoA-I induced lipid efflux was determined as the difference between the mean % of CL 
efflux in medium containing apoA-I and the average % of lipid efflux found in wells 
without apoA-I (background efflux).  The time course of apoA-I induced CL release (as 
% total) was fitted by linear regression to estimate the corresponding rate of efflux.    
 
v. Phospholipid efflux Assays.   
To measure choline-labeled phospholipid efflux, macrophages or adipocytes were labeled 
with [3H]-choline [5 µCi/mL] in 2.5% FBS-M199 for 22-24 h.  At time zero, 75 µg/mL 
of recombinant apoA-I in DMEM-0.05% BSA, or buffer as background, was added to 
each well.  Aliquots of media were collected at indicated time points and at the final time 
point the whole well homogenate and remaining media collected.  The organic phase of 
media (or homogenate) containing radiolabeled lipids was then extracted from the 
aqueous phase containing the un-incorporated choline by the Folch method [123].  The 
organic phase lipids were then dryed completely and the [3H]-choline labeled PL were 
measured by liquid scintillation counting.    
The % of cellular PL efflux was calculated from the amounts of [3H]-choline labeled PL 
determined in media and cell homogenates as: 
% of lipid efflux = cpm media*100/(cpm media + cpm homogenate).  The mean values 
and standard deviations of apoA-I induced PL efflux were determined as indicated for CL 
efflux.  
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vi. Lipid efflux inhibition assays.  
Assays were performed as described above however drugs were pre-incubated with cells 
1-2 h prior to experiment by replacing labeling media with DMEM-0.05% BSA 
experimental media in the presence of BFA (10 µg/mL), GLYB (500 µM), 
BLT1(10 µM), BLT4 (150 µM) or DMSO as a control.  At time zero, the experimental 
media was re-added with 75 µg/mL of recombinant apoA-I or without apoA-I for a 
background efflux level.  Media and homogenate was collected and protein and lipids 
analyzed as described above.  
To calculate the inhibition of each drug on apoA-I dependent efflux, the efflux slope 
values of each drug were determined as described above for CL and PL efflux assays.   
These apoA-I dependent % efflux values were used to calculate inhibition according to: 
(% inhibition = 100*rate drug / rate control) for each drug replicate.  The values were 
then averaged and expressed as mean with the corresponding standard deviations 
calculated through propagation of error. 
 
vii. Efflux normalization by ABCA1 protein level.   
A semi-quantitative analysis of cellular ABCA1 protein was done by western blotting of 
aliquots of homogenates.  The samples analyzed were obtained from some of the wells 
not used for lipid efflux studies but contained in the same plate.  Protein concentration of 
homogenates were determined as mentioned section III.iii.  The volumes of homogenate 
separated by electrophoresis were adjusted such that equal amounts of protein (70 µg) 
were loaded for all samples.  Proteins were then transferred to nitrocellulose membrane 
and blotted with rabbit polyclonal anti-ABCA1 (Novus).  All samples to be compared 
(control and GW3965 treated) and macrophages (control and 8-Br-cAMP treated), were 
loaded within the same gels and analyzed from the same blots.  After detection by 
chemiluminescence the films were scanned and the band intensities determined by 
densitometry using AlphaEase software (Santa Clara, CA).  The band intensities in 
arbitrary density units (a.u.) were directly compared within the same blots.  To compare 
the results of different blots the band intensities were first normalized using the intensity 
of adipocytes control as internal reference.  CL efflux rate was calculated as described 
previously and the efflux of each well normalized by mg cellular protein per well.   
To normalize the CL efflux rate by ABCA1 protein levels, the a.u. of each sample 
determined from blots were divided into the apoA-I dependent CL efflux rate determined 
above. Thus, (nmol CL efflux or % CL Efflux)/h•mg cell protein ÷  (ABCA1 a.u.)
 
/mg 
cell protein  = Efflux Rate/[ABCA1].  
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viii. ApoA-I, apoLp-III and Thrx recombinant proteins.  
Full-length mature human apoA-I was previously cloned into a vector which incorporates 
an N-terminal tag containing six-His residues and a five amino acid recognition sequence 
(RRASV) for the catalytic subunit of cAMP-dependent protein kinase A (PKA) [121].   
The protein size and identity was confirmed as previously described [121].  The presence 
of an accessible PKA phosphorylation site on the recombinant apoA-I was confirmed by 
in vitro method previously described [121, 124].  
Wild-type L. migratoria apolipophorin-III (apoLp-III) cloned into pET32a as previously 
described [125] was transferred to a pET30 (Novagen, Inc.) expression vector which 
incorporates an N-terminal six-His residue tag with primers designed to code for the 
same N-terminal PKA recognition site as pka-apoA-I described above.  The final 
sequence encoded a protein of 217 residues with a mass of 23 kDa.  Similarly, 
thioredoxin (Thrx) was transferred to the same vector incorporating N-terminal His- and 
PKA recognition site- tags and coding for a protein of 162 residues with a mass of 
17.7 kDa.  The proteins were expressed separately in Escherichia coli and purified by Ni-
affinity chromatography using standard procedures.  The protein sizes and identities were 
confirmed by SDS-PAGE and MALDI-TOF peptide mass fingerprinting on a Voyager 
DE-Pro mass spectrometer in the OSU Core Facility.   
 
ix. Cellular Recycling of ApoA-I 
 
ApoA-I Recycling Assay. 
3T3 L-1 adipocytes cultured in six well dishes were radiolabeled by incubation for 5 h at 
37⁰C with 75 µCi/well of [32P]-orthophosphate (carrier free) in phosphate-free DMEM 
containing 0.05% BSA.  The wells were then washed and fresh media containing 
isoproterenol (10 µg/ml) with pka-tagged recombinant proteins were added back to each 
well. After a brief incubation period, the well media was collected and centrifuged at 
10,000 rpm for 10 min to pellet any floating cells.  Aliquots of medium were used to 
measure the amount of glycerol (Infinity Triglyceride Reagent) released by cells into the 
media as an indicator of cell lipolytic rate.  The media was then either run onto SDS-
PAGE directly or first purified using Ni-affinity chromatography, then separated by gel 
electrophoresis.  Gels were dryed and any pka-tag phosphorylation visualized using 
autoradiography. 
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Saturation of apoA-I recycling.  
3T3 L-1 adipocytes were radiolabeled as described above.  To measure the saturation of 
apoA-I recycling in adipocytes, fresh media containing pka-apoA-I was added to each 
well and allowed to incubate for 40 minutes at 37⁰C.  After 40 minutes, the cell 
experimental medium was analyzed as described above for pka-apoA-I 
[32P]-phosphorylation indicative of apoA-I cellular uptake and re-secretion. 
 
 Competition of native apoA-I, apoLp-III and Thrx with apoA-I for Recycling  
Adipocytes were [32P]-radiolabeled as described above and pka-apoA-I added alone or in 
combination with human apoA-I, apoLp-III or Thrx to cells to monitor the ability of these 
proteins to compete with pka-apoA-I for recycling.  For competition with human apoA-I, 
pka-apoA-I (40 µg/mL) was added with increasing concentrations of purified human 
apoA-I.  As a control one well was incubated with 40 µg/mL human apoA-I and 0 µg of 
pka-apoA-I.  For competition with apoLp-III or Thrx, pka-apoA-I (1.5 nmol), pka-apoLp-
III (3-6 nmol) or pka-Thrx (3-6 nmol) was added to the media of each well along with 
10 µg/mL isoproterenol (to enhance PKA activity).  After 40-60 minutes the cell media 
was collected and analyzed as mentioned previously to monitor for recycling.  
 
Effect of Lipid Efflux Inhibitors on Recycling  
Adipocytes were [32P]-radiolabeled in phosphate-free KRBH containing 0.005% BSA.  
To monitor the effect of lipid efflux inhibition on recycling, inhibiting concentrations of 
BFA and BLT1 were added to the previously described pka-apoA-I recycling assay.  
BFA (10 µg/ml) or BLT1 (10 µM) were allowed to pre-incubate 2 h prior to the end of 
the labeling period and the assay initiated by the addition of 50 µg/mL pka-apoA-I.  The 
cell media was collected after 10, 20 and 40 min and the pka-apoA-I phosphorylation 
analyzed from purified media as previously described.  Glycerol levels were measured 
(Infinity Triglycerides Reagent, Thermo) by analyzing aliquots of media to ensure that 
drug incubation did not result in changes in the lipolytic rate.  
 
Effect of antibody to ATP synthase subunit β on pka-apoA-I Recycling  
Adipocytes were [32P]-radiolabeled as described previously. 1 h prior to the pka-apoA-I 
addition, the labeling medium was replaced with fresh medium containing indicated 
amounts of antibody to ATPase subunit β (either clone 3E8 or 3D5).  Pka-apoA-I 
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(40 µg/mL) was added to the media of each well after the labeling and antibody 
incubation periods.  Aliquots of the media were collected after 60 min and used to 
analyze both pka-apoA-I and glycerol release into the media as describe previously.   
 
x. Relationship of Phospholipid Efflux to ApoA-I Recycling.  
ApoA-I was incubated with radiolabeled and antibody pre-incubated adipocytes as 
described above.  After 60 min cell media was collected and apoA-I associated lipids 
purified by Ni-affinity chromatography.  Protein concentrations of eluants were 
determined by UV280nm and confirmation of purity and concentration was obtained by 
SDS-PAGE.   
[32P]-labeled phospholipids were extracted from free phosphate and protein fractions by 
modified Folch [123].  Briefly 20 parts chloroform:methanol [2:1] were added to 1 part 
protein eluant and mixed.  Then choloroform:methanol [2:1] was added such that the 
organic to eluant ratio became 5:1 and mixed.  After separation the upper aqueous phase 
containing free phosphate and the interface containing proteins were discarded. The 
lower organic phase containing phospholipids was completely dried then counted using 
scintillation counting.  Counts were then normalized by the amount of apoA-I absorbance 
at UV280nm.  Thin layer chromatography was used to confirm incorporation of [32P] into 
phospholipids. 
 
xi. Relationship of Cholesterol Efflux to ApoA-I Recycling.   
To monitor the relationship of apoA-I recycling and apoA-I dependent cholesterol efflux, 
recycling and efflux assays were performed in parallel with and without anti-ATPase β.  
3T3 L-1 adipocytes were radiolabeled with either [3H]-cholesterol or 
[32P]-orthophosphate.  For CL efflux assays, cells were labeled with [3H]-cholesterol for 
19 h in 2.5% FBS-DMEM followed by a 5 h labeling with [3H]-cholesterol in 
0.05% BSA-DMEM.  For recycling assays adipocyte were [32P]-radiolabeled in 
0.05% BSA-DMEM for 4 h.  Next all cells were either pre-incubated with or without 
60 µg anti-ATPase β clone 3D5 for 1 h prior to pka-apoA-I addition.  Recombinant 
pka-apoA-I was then added to cell media and incubated for either 5 h or 1 h.   
For recycling assay analysis, 1 h media was collected and apoA-I purified by Ni-affinity 
chromatography.  Protein concentration was determined by UV280nm and confirmation of 
purity and concentration was obtained by SDS-PAGE.  Gels were dried and subjected to 
autoradiography and densitometry used to confirm antibody inhibition of apoA-I cell 
entry and resecretion. 
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For efflux assay analysis, media was collected at indicated time points, briefly spun and 
[3H]-cholesterol efflux determined by scintillation counting.  After allowing efflux to 
proceed for 5 h the wells were washed then cholesterol extracted into isopropanol and 
counted.  Whole well [3H]-cholesterol and % of cellular efflux were determined as 
described above for cholesterol efflux assays.  
  
xii. Statistical Analysis 
The statistical significance of differences were determined between means of control and 
treated sample data using the Student’s t-test (Graphpad).   
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CHAPTER IV 
 
 
CHARACTERIZATION OF APOA-I DEPENDENT LIPID EFFLUX IN 
ADIPOCYTES, ROLE OF ABCA1 
 
Abstract 
Adipose tissue is a major reservoir of cholesterol and, as such, it may play a significant 
role in cholesterol homeostasis. The goals of the present studies were to obtain a 
quantitative characterization of apolipoprotein A-I (apoA-I) dependent lipid efflux from 
adipocytes and examine the role of ATP-binding cassette transporter A1 (ABCA1) in this 
process.  The rates of apoA-I induced cholesterol and phospholipid efflux were 
determined.  To allow a comparative analysis, parallel experiments were also performed 
in macrophages.  These studies showed that when the rates are normalized by cellular 
protein or by ABCA1 content, apoA-I induces cholesterol efflux from adipocytes at 
similar rates as from macrophages.  Enhancement of the expression of ABCA1 increased 
the rates of cholesterol efflux from both adipocytes and macrophages. However, the 
results also suggested that a non-ABCA1 dependent mechanism could make significant 
contributions to the basal (basal levels of ABCA1) rate of apoA-I dependent cholesterol 
efflux. Furthermore, the study of the effect of inhibitors of lipid efflux showed that 
glyburide and brefeldin A, which affect ABCA1 function, exerted strong and similar 
inhibitory effects on lipid efflux from both adipocytes and macrophages, whereas BLT1, 
an SRB-I inhibitor, only exerted a moderate inhibition.  Overall these studies suggests 
that ABCA1 plays a major role in apoA-I dependent lipid efflux from adipocytes and 
showed high similarities between the abilities of adipocytes and macrophages to release 
cholesterol in an apoA-I dependent fashion. 
Keywords: apoA-I, adipocyte, macrophage, lipid efflux, ABCA1 
Abbreviations  used:  ApoA-I,  apolipoprotein  A-I;  ABCA1, ATP-binding cassette 
transporter A1; GLYB, glyburide; BFA, Brefeldin A; LXR, Liver X Receptor; BLT, 
block lipid transport; BSA,  bovine serum albumin; FBS, fetal bovine serum; CL, 
cholesterol; PL, phospholipid; Scavenger Receptor-BI, SRBI
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Results 
i. Lipid efflux from adipocytes.   
Previous works have shown that incubation of 3T3 L-1 adipocytes with apoA-I results in 
both CL and PL efflux into the media [23, 24].  Although the previous studies have 
shown adipocytes capable of apoA-I-induced lipid efflux, no studies have fully 
characterized the rate, stoichiometry or quantitative scale of this process.  In order to 
characterize apoA-I-dependent efflux from adipocytes, the rate of cholesterol release 
from [3H]-cholesterol-labeled adipocytes upon apoA-I incubation was determined.  
Similarly cells radiolabeled with [3H]-choline allowed characterization of the choline-
containing PL efflux rate.  Parallel experiments were also performed in the murine 
macrophage cell line J774 to allow the comparison of adipocytes to a well-studied cell-
type.  Efflux specific to apoA-I induction was calculated by subtracting the background 
efflux levels from efflux in the presence of apoA-I (Fig. 3A, 3B).  The results show that 
lipid efflux from both adipocytes and macrophages responds to apoA-I induction in a 
linear fashion.  Adipocytes efflux a higher percentage of their cellular PL compared to 
macrophages but the opposite is true for percent CL efflux in response to apoA-I 
incubation. 
 
Figure 3.  Lipid Efflux from Adipocytes and Macrophages.  3T3 L-1 adipocytes and J774 macrophages 
were labeled with A. [3H]-cholesterol or B. [3H]-choline and assayed for efflux into the media upon 
75 µg/mL apoA-I incubation (,) or with buffer (,) as described in Methods section III.iv,v. The 
‘apoA-I induced’ values for adipocytes (open shapes) and macrophage (filled shapes) data points were 
calculated by subtracting the background efflux at a particular time point from efflux of wells with apoA-I 
added at that same time point.  Efflux was plotted versus time and error bars represent the mean ± s.d. for 
two PL and six CL assays in adipocytes as well as two PL and four CL experiments in macrophages with at 
least triplicates per experiment time point. 
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ii. Drug induction of ABCA1 increases CL efflux.   
Studies have shown that addition of cAMP analogues stimulates lipid efflux through the 
ABCA1-mediated pathway in macrophages [9, 21, 84, 126, 127].  Therefore the cAMP 
analogue 8-Br-cAMP (cAMP) was added to cells to enhance the ABCA1-mediated 
pathway in J774 macrophages (Fig. 4A).  As expected this resulted in an increase 
(2.3 fold, p< 0.001) in apoA-I induced CL efflux above untreated macrophages.  cAMP is 
known to increase both ABCA1 mRNA and protein levels in macrophages [9, 84].  
Similarly, research has shown that LXR agonists, such as GW3965, increase ABCA1 
mRNA levels in adipocytes [128-130].  Therefore the LXR-agonist GW3965 was added 
to adipocytes for comparison to the cAMP-treated macrophages and apoA-I dependent 
efflux monitored (Fig. 4B).   
 
Figure 4.  ABCA1 drug induction increases CL efflux from adipocytes.  Experiments in A. 
macrophages or B. adipocytes were performed as before but cells were treated with either LXR-agonist 
180µM 8-Br-cAMP (cAMP) or 2µM GW3965 (LXR) or buffer (CONT) 24 hours prior to assays.  ApoA-I 
induced rates of lipid efflux were determined as mentioned previously using the slopes of the CL efflux 
assay graphs.  The rates were then normalized by mg homogenate protein per well to obtained the average 
rates of % efflux per hour per mg homogenate protein.  The bars represent the mean of four experiments for 
macrophage (n=15) and three experiments for adipocytes (n=19) for each treatment ± s.d.  Significant 
differences (***, p< 0.001) were determined by student’s t-test between the means of control and treated 
samples from both adipocytes and macrophages.    
 
 
The results showed that the LXR-agonist increased (1.5 fold, p< 0.001) the apoA-I 
dependent CL efflux from adipocytes similar to the cAMP-induction of CL efflux from 
macrophages.  The rates of CL efflux were normalized by the amount of homogenate 
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protein per sample in order to adjust for differences in protein content per culture well 
(Fig. 4).  This normalization did not affect the fold difference within adipocytes (controls 
to LXR agonist-treated) or within macrophage (controls to cAMP-treated) efflux but did 
narrow the difference between adipocytes and macrophages.  This is reflective of a 
variation across the cell types in protein content per culture well and provides one 
standard for comparison of the assays from adipocytes and macrophages. 
 
iii. Molar rates of efflux from adipocytes compared to macrophages.  
Although the macrophages efflux a higher percentage of CL and adipocytes more PL, the 
percent of cellular (unit) cannot be interpreted to mean that macrophages efflux more CL 
and adipocytes more PL.  To be able to compare in such a way, the total lipid contents of 
the different cell-types first need to be determined.  Because adipocytes are expected to 
store larger amounts of cholesterol, conversion of lipid efflux as a percentage into molar 
lipid efflux was necessary in order to compare the efflux levels across cell types.  The 
first step, in converting the units of efflux from percentage to moles, involved 
determining the homogenate lipid levels of both adipocytes and macrophages.  The total 
lipid content of cells was determined by extraction of homogenate lipids, TLC separation, 
re-extraction, and finally quantified by assay as described in Methods section III.iii.  All 
PL species were extracted from one TLC spot but the phospholipase D colorimetric assay 
measures mainly the phosphatidylcholine (PC) and sphingomyelin (SM) present.  The 
resulting values for total CL and PC/SM (representative of overall PL efflux) in the 
homogenates were summarized in table 2.  The difference in control and treated (either 
with cAMP or GW3965) homogenate lipid compositions were found to show no 
significant difference in lipid compositions and therefore all homogenate values within 
cell-types were averaged together.  As expected, measured homogenate cholesterol levels 
showed that adipocytes contain more cholesterol per mg protein with a CL/PL ratio near 
one compared to macrophages with a CL/PL ratio closer to 0.75.  The quantification for 
macrophages was consistent with previous reports of J774 homogenate lipid 
compositions [131].  The amount of homogenate lipid was then used to calculate the 
moles of CL and PL released into the media (table 2).  The conversion of apoA-I 
dependent lipid efflux from a percentage to a molar efflux rate resulted in further 
equalization of efflux levels from both control adipocytes and macrophages although the 
treatment of macrophages with cAMP was still higher (1.3 fold) than the rate of CL 
efflux from LXR-treated adipocytes.  A similar analysis of apoA-I dependent PL efflux 
from both adipocytes and macrophages was performed as described previously and is 
also summarized in table 2. 
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Table 2. 
Homogenate Lipid Compositions and apoA-I dependent efflux of 3T3 L-1 adipocytes and J774 macrophages. 
 Adipocytes 
LXR-treated 
Adipocytes Macrophages 
cAMP-treated 
Macrophages 
a Cellular Phospholipid 
(nmol PC/SM per mg protein) 
45.7 ± 8.3      
(25) ―
†
 
33.9 ± 8.4          
(34) ― 
a Cellular Cholesterol 
(nmol CL per mg protein) 
46.2 ± 11.2  
(29) ― 
25.7 ± 7.6          
(32) ― 
b Phospholipid Efflux 
(nmol PC/SM per h • mg protein) 
0.100 ± 0.018 
(33) n.d. 
0.0409 ± 0.010    
(45) 
0.159 ± 0.042  
(44) 
b Cholesterol Efflux 
(nmol CL per h • mg protein) 
0.210 ± 0.051 
(138) 
0.309 ± 0.077 
(46) 
0.165 ± 0.050      
(68) 
0.387 ± 0.12    
(70) 
CL/PL 
Efflux ratio 
2.1 ± 0.64 n.d. 4.0 ± 1.6 2.4 ± 1.0 
a Cellular contents of choline-containing phospholipids (PC and SM) and cholesterol (CL) were determined 
as indicated in Methods section iii.  Data are expressed as mean values ± s.d. The number of independent 
data points, different wells, is included in parenthesis.  
b The rates of lipid efflux (mean ± s.d.) were obtained by linear regression. Data from 5 experiments (J774 
cells) and 8 experiments using 3T3 L-1 cells with 3 experiments for GW3965 (LXR)-treated 3T3 L-1 cells 
are included.  The number of data points used in the calculation of the rates is included in parenthesis.  
The efflux stoichiometry in moles of CL per mol of PL was calculated from the average rates of efflux. The 
standard deviation of the CL/PL ratio was estimated from the standard deviations of the rates of CL and PL 
efflux and the propagation of error equation.  
n.d., not determined. 
†the homogenate lipid compositions for treated cells were insignificantly different than values for control 
cells and were therefore represented as mean ± s.d. in the control cell columns.  
 
 
iv. Comparison of adipocyte and macrophage lipid efflux ratios (CL:PL).   
The ability of adipocytes to efflux both CL and PL is an important establishment because 
it highlights the ability of adipocytes to contribute to nascent HDL levels.  Furthermore, 
apoA-I-dependent efflux ratios (CL:PL) from adipocytes evaluated against macrophages 
allows a comparative analysis of each cell type’s efflux pathway.  The majority of 
apoA-I-dependent efflux from macrophages occurs via an ABCA1-mediated pathway 
thus the CL to PL efflux should have a characteristic ratio [18-20, 131].  To analyze the 
newly formed lipoparticle CL to PL composition, the quantitative lipid efflux assays 
mentioned previously were used to calculate the molar CL to PL ratios for adipocytes or 
macrophages (table 2).  Since just the CL and PC/SM TLC spots were analyzed by 
colorimetric assay, the resulting ratio of efflux is actually CL to PC/SM.  However, PC 
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has been shown to be the major phospholipid induced to efflux to apoA-I, thus these 
ratios are expected to be representative of the overall CL:PL efflux ratios [19, 132].  
Although homogenates contained CL:PL ratios closer to 0.8-1.0 in both macrophages and 
adipocytes, ratios of CL:PL efflux changed significantly.  Consistent with previous 
reports, control macrophages demonstrated an efflux ratio close to ~4 but in a cAMP-
treated state the efflux ratio approached 2 [18-20, 131].  Similar to cAMP-macrophages 
the adipocyte CL:PL ratio in table 2 is approximately 2.  Furthermore the ratio of CL:PL 
for cAMP-treated macrophages in the absence of control levels of efflux is also very 
similar to the ratio for adipocytes (1.85 ± 1.3).  Thus, apoA-I elicits CL and PL efflux 
from adipocytes at ratios similar to the lipid efflux ratios of the ABCA1-mediated apoA-I 
dependent efflux pathway of cAMP-macrophages. 
 
v. Normalization of lipid efflux by ABCA1 protein levels in adipocytes and 
macrophages. 
Adipocyte 3T3 L-1 cells have previously been shown to express ABCA1 and efflux CL 
upon apoA-I incubation [23, 24, 27].  However, although the mRNA expression levels 
have been studied in relation to efflux levels, the protein expression levels have not.  The 
amount of ABCA1 mRNA relative to protein appears to differ by tissue type and protein 
levels are regulated on both the transcriptional level and by protein degradation [17, 133, 
134].  Thus it has been concluded that analysis of ABCA1 mRNA levels cannot be solely 
used to predict efflux ability of cells [21].  In agreement with this, research has shown 
disparity between the level of ABCA1 mRNA levels and efflux levels in adipocytes [24].     
The stoichiometric similarity of adipocyte lipid efflux compared to macrophages suggests 
the involvement of ABCA1 in apoA-I dependent lipid efflux from adipocytes.  To further 
investigate this, lipid efflux assays were performed simultaneously with western blot 
analysis of ABCA1 from adipocyte and macrophage homogenates.  Aliquots of 
homogenates were used for ABCA1 blotting by combining adipocytes and macrophage 
samples into different lanes within the same blots such that the adipocyte ABCA1 
concentration could be determined relative to macrophage concentrations.  The 
representative blot in figure 5A shows that ABCA1 is present in both adipocytes and 
macrophages as expected.  As summarized by the graph of anti-ABCA1 relative densities 
from combined experiments, it is also apparent that the level of expression is increased in 
LXR-agonist treated adipocytes and cAMP-treated macrophages compared to controls 
(Fig. 5B).  Also adipocytes seem to express ABCA1 at slightly higher levels than 
macrophages in the control states, but cAMP seems to result in a much stronger induction 
of ABCA1 protein expression in macrophages than LXR-treatment of adipocytes. 
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Figure 5.  Adipocyte and Macrophage ABCA1 Protein Expression Levels.  A. Comparison of ABCA1 
protein levels from adipocytes to macrophages.  3T3 L-1 adipocyte and J774 macrophage homogenate 
samples were loaded onto SDS-PAGE and transferred to nitrocellulose for western blotting with anti-
ABCA1.  Amounts loaded per lane were normalized by the protein concentrations of homogenates.  
Samples were loaded such that each lane contained approximately 70µg of homogenate protein.  Western 
blot is demonstrative of samples from 3 separate experiments with n=7 for each treatment state.  Samples to 
be compared to each other were run within the same blot and normalized by homogenate protein per lane.  
Blot is representative of 4-6 technical replicate blots per sample per independent experiment with 3 
experiments per treatment and cell type.  B.   Western blot densities of anti-ABCA1.  Blots were 
normalized to each other by internal sample densities and arbitrary units combined into replicate samples.  
Replicates samples were combined by treatment and cell type and bars represent means ± s.d. for three 
independent experiments (n=7).  Significant differences (p < 0.001) were determined by student’s t-test 
between the means of control and treated samples from both adipocytes and macrophages. 
 
 
In order to evaluate the efflux rate per ABCA1, the densitometric arbitrary units (a.u.) 
representing ABCA1 protein levels were then used to normalize the CL and PL efflux 
rates obtained from assays (Fig. 6A, 6B).  The ABCA1 normalized CL efflux rate shows 
that adipocytes efflux at an identical rate as macrophages per ABCA1.  The results also 
show an interesting pattern for CL efflux per ABCA1 protein (Fig. 6B).  Induction of 
ABCA1 protein expression by either the LXR agonist or cAMP resulted in a decrease in 
efficiency of efflux per ABCA1.  This large difference seems to implicate either an 
apoA-I induced but ABCA1-independent mechanism in control cells or that induction of 
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ABCA1 protein expression is not the only determinant in stimulation of cholesterol efflux 
to apoA-I.  It is important to remember that this ratio does not represent overall efflux but 
instead similar levels of apoA-I induced efflux normalized by low levels of ABCA1 
expression (Fig. 5B, 6A).   
Despite these differences, the rate of cholesterol efflux normalized by ABCA1 protein 
was similar in the LXR-agonist treated adipocytes compared to cAMP-treated 
macrophages (Fig. 6B).  Because cAMP-treated macrophages are believed to efflux lipids 
to apoA-I mainly through ABCA1, this is further evidence that adipocytes also efflux 
lipids to apoA-I mainly through an ABCA1-mediated pathway. 
 
 
Figure 6.  Effect of ABCA1 expression levels on apoA-I dependent CL Efflux from Adipocytes or 
Macrophages.  A. Rates of CL efflux normalized by total cellular protein content. The experiments were 
performed as indicated in methods.  Adipocytes and macrophages were treated with either the LXR-
agonist, 2µM GW3965 (LXR), or 180µM 8-Br-cAMP (cAMP), respectively, or with buffer (CONT) for 
24h prior to assays.  The rates of apoA-I induced CL efflux normalized by protein content were determined 
from the slopes of the efflux assay time courses (% of cellular CL released into medium vs time).   The 
average rates were then converted into nmoles of CL/h•mg cell protein using the cholesterol contents of the 
cells.  The mean values ± s.d. for adipocytes were obtained from three independent experiments and 
include 19 data points.  The data for macrophages were obtained from four experiments (n=15).  
Significant differences (***, p < 0.001; **, p < 0.005) were determined by student’s t-test between the 
means of control and treated samples for both adipocytes and macrophages.  B. Rates of CL efflux 
normalized by ABCA1 protein levels.  The average rates of apoA-I induced CL efflux shown in figure 6A 
were converted into nmoles of CL/h•ABCA1 protein using the average relative levels of ABCA1 
expression shown in the figure 5B.  Each bar represents the mean  ± s.d. which was calculated using the 
propagation of errors equation and the standard deviations of ABCA1 levels and rates of efflux.  The 
differences between the means of control and treated cells were significant (***, p < 0.001) for both 
adipocytes and macrophages. 
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vi. Inhibition of apoA-I dependent lipid efflux from adipocytes by ABCA1-targeting 
drugs.   
To further investigate the role of ABCA1 in apoA-I dependent efflux from adipocytes, 
efflux assays were performed in the presence of several drugs known to reduce apoA-I 
dependent lipid efflux via inhibition of the ABCA1 transporter.  
BFA is a drug known to block transport vesicle formation [29, 30, 135-137].  While BFA 
does not inhibit the endocytic transport of all proteins [136, 138, 139], it has been shown 
to inhibit the recycling of ABCA1 [31, 140].  Use of BFA allows manipulation of 
adipocyte ABCA1 availability to participate in efflux pathways.  Although BFA has been 
shown to inhibit ABCA1, its broad disruption of cellular structures may cause disruption 
of lipid efflux from adipocytes via other unknown mechanisms.  Therefore other 
ABCA1-targeting inhibitors were also used.  The block lipid transport (BLT) family of 
inhibitors was first developed by Nieland et. al. while scanning for inhibitors that block 
the SRBI-mediated lipid transfer in cells [141].  SRBI mediates cholesterol ester uptake 
from, or CL efflux to HDL [76, 77].  However, while it was found that BLT1-3 and 
BLT5 remained highly specific to SRBI-mediated CL efflux, BLT4 cross inhibited 
ABCA1-mediated CL efflux [142].  Therefore in these adipocyte lipid efflux assays, 
BLT4 is used as a unique inhibitor of both the ABCA1 and SRBI pathways of efflux.  
Also BLT1 was used as a specific inhibitor of the non-ABCA1 SRBI-mediated CL efflux 
(to HDL) pathway.  Finally, the sulfonylurea glyburide (GLYB) which is known to block 
several ABC transporters including ABCA1 was used [5, 85, 143-148].  GLYB is a 
powerful inhibitor for use in the apoA-I dependent lipid efflux assays to elucidate if 
apoA-I-induced efflux from adipocytes involves ABCA1.   
Experiments to analyze the effects of these drugs on apoA-I dependent CL and PL efflux 
involved similar efflux assays as described previously but were performed in the presence 
of inhibiting BFA, GLYB, BLT4 or BLT1 concentrations.  The drugs were allowed to 
preincubate with the cells prior to the addition of apoA-I.  The resulting efflux versus 
time graphs were used to obtain the rate of efflux for each drug and control.  To calculate 
the inhibition that each drug imposed on apoA-I dependent lipid efflux, the efflux rates of 
each drug were divided by the rates of the controls.  The resulting inhibitions were 
expressed as a percent of the control efflux for CL or PL across both adipocyte and 
macrophages (Fig. 7). 
Figure 7 shows strong inhibition by GLYB and BFA in both macrophages and adipocytes 
of the PL and CL efflux induced by apoA-I.  BFA falls within the expected (~58-85%) 
inhibition compared to what has been studied previously for fibroblasts but is higher than 
previous work in macrophages [140, 149].  This could be because previous works in 
macrophages were limited to 2 hours of inhibition and highlight the time-sensitivity of 
BFA’s effect.  GLYB also strongly inhibited CL and PL efflux of both macrophages and 
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adipocytes.  In addition to GLYB and BFA, adipocytes were also incubated with BLT1 
and BLT4.  Similar to GLYB and BFA, BLT4 also inhibited CL efflux but was only half 
as effective in inhibition of PL efflux.  BLT4 had been reported to strongly inhibit CL 
release to apoA-I however its effects on PL efflux had not been examined until now 
[142].  Similarly BLT1 slightly blocked CL efflux but its inhibition of PL efflux from 
adipocytes was much less pronounced.  It is interesting to note that while the BLT drugs 
inhibited cholesterol efflux from adipocytes more than they inhibited phospholipid efflux, 
the opposite is true of GLYB and BFA.   
 
 
Figure 7.  Effect of ABCA1-inhibiting drugs on apoA-I dependent efflux from adipocytes compared 
to macrophages.  The effect of the drugs GLYB (500µM), BFA (36µM), BLT1 (10µM)  and BLT4 
(150µM)  on apoA-I-dependent cholesterol efflux from macrophages and adipocytes was determined as 
described in Methods section III.vi.  A. Inhibition of apoA-I induced cholesterol efflux from adipocytes and 
macrophages.  The bars represent the mean ± the s.d. of 2-4 independent experiments for adipocytes and 1 
experiment for macrophages with n=6-14 for adipocytes and n=3 for macrophages.  B. Effects of the same 
drugs on inhibition of apoA-I dependent phospholipid efflux from adipocytes and macrophages.  The bars 
represent the mean ± s.d. of one experiment with n=3-4.   
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It has been reported that, in the case of glyburide inhibition of PL efflux, the inhibition 
seen is due largely to increases in background (i.e., lipid efflux to apoA-I free media) 
rather than large decreases in apoA-I induced lipid efflux [111, 142].  However for most 
of the efflux assay experiments, the majority of each drug’s inhibition resulted from 
decreased efflux in the presence of apoA-I rather than in than increases in background 
levels of efflux (data not shown).  In the few cases where increases in background 
contributed to the majority of the inhibition observed, the overall % inhibition values 
showed no significant difference from other experiments.  Thus the inhibitions by these 
drugs most likely reflect a real inhibition of ABCA1-mediated apoA-I dependent lipid 
efflux in which any experimental variability in background efflux levels are appropriately 
controlled for, thus giving an accurate reflection of the inhibition ability of each drug. 
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CHAPTER V 
 
 
THE β-SUBUNIT OF ATP SYNTHASE CONTROLS CELLULAR UPTAKE AND 
RESECRETION OF APOA-I IN ADIPOCYTES BUT DOES NOT CONTROL APOA-I 
INDUCED LIPID EFFLUX 
 
Abstract 
The initial steps in the formation of nascent HDL involve lipid loading of apoA-I.  
Cellular uptake of apoA-I may be important for the assembly of HDL and may also 
regulate the circulating levels of the apoA-I and/or HDL.  ApoA-I is shown here to be 
internalized and re-secreted (apoA-I recycling) by adipocytes in a saturatable and specific 
process.  ABCA1 is involved in cellular binding, uptake and lipidation of apoA-I.  The 
following studies however, suggest apoA-I recycling is a receptor-mediated process 
independent of ABCA1 function [121].  Additional results show that a monoclonal 
antibody against the β-subunit of ATP synthase blocks apoA-I recycling but has no effect 
on the rate of apoA-I induced cholesterol or phospholipid efflux.  It is concluded that a) 
ATP synthase β, which had been previously identified as an apoA-I receptor [150], is 
directly involved in cellular recycling of apoA-I and, b) cellular recycling of apoA-I is 
not required for apoA-I induced lipid efflux demonstrating that apolipoprotein lipidation 
and recycling are independent processes.   
Keywords: apoA-I, adipocyte, lipid efflux, ABCA1, recycling, ATP synthase β 
Abbreviations  used:  ApoA-I,  apolipoprotein  A-I;  ABCA1, ATP-binding cassette 
transporter A1; BFA, Brefeldin A; BSA,  bovine serum albumin; FBS, fetal bovine 
serum; apoLp-III, apolipophorin III; Thrx, thioredoxin; ATPase β, ATP synthase F1 
subunit β;   
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Results 
 
i. Pka-ApoA-I enters the cell by a saturatable and specific pathway.  
In order to study the uptake and re-secretion of apoA-I and its role in the process of 
efflux a recombinant protein was developed containing full length mature human apoA-I 
and two tags including a His-tag for protein purification and a protein kinase (PKA) 
consensus sequence containing tag [27, 28].  The pka-tag allows monitoring of protein 
cell entry.  The concept of the assay is based on the idea that cell entry of the tagged 
protein allows for its phosphorylation by intracellular PKA.  Also, if the protein is re-
secreted, the level of the tag-phosphorylation analyzed from the media is related to the 
level of protein recycling.  By radiolabeling the ATP pool with [32P]-orthophosphate, the 
phosphorylated pka-apoA-I collected from cell media could then be visualized by 
autoradiography allowing for direct evidence of apoA-I recycling.  
To examine the levels to which apoA-I might be taken up by the cell and re-secreted into 
the cellular medium, adipocytes were [32P]-radiolabeled and increasing amounts of 
pka-apoA-I were added to the experimental media.  Following a 30 minute incubation 
time, media was collected and phosphorylation of pka-apoA-I analyzed.  The coomassie 
gel (Fig. 8A) shows the increasing levels of protein added to the cell media while the 
autoradiogram (Fig. 8B) shows increasing levels of phosphorylation.  These results 
definitively show that apoA-I is recycled in adipocytes.  Importantly, comparison of the 
last two lanes of both the gel and autoradiogram reveal that the increase in 
phosphorylation becomes saturated.  To better visualize this saturation, the densitometric 
phosphorylation a.u. of pka-apoA-I were normalized by the protein amount and graphed 
to examine the level of apoA-I uptake and re-secretion (Fig. 8C).  From the graph, apoA-I 
appears to be readily entering and exiting the cell until the process starts saturating near 
45 µg/mL.  The two major possibilities for uptake of apoA-I involve either receptor-
mediated endocytosis and/or bulk phase endocytosis through membrane recycling.  Bulk 
phase endocytosis would involve binding of apoA-I to the plasma membrane and slow 
internalization as the membrane turns over.  Instead the saturation of uptake seen from 
increasing apoA-I concentration in the experimental media seems to implicate a 
saturatable receptor mediated pathway (KD ~1µM). 
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Figure 8. Saturation of apoA-I entry and exit from the cell.  Recycling assays of pka-apoAI were 
performed in [32P]-prelabeled adipocytes as described in Methods section III.ix.  A. Coomassie stained gel 
representing 10% of each well’s media per lane.  Arrow indicates the 31kDa pka-apoA-I.  B. 
Autoradiogram of the gel in A showing increased levels of phosphorylation per protein.  C. Graph of the 
level of pka-apoA-I phosphorylation (from part B) normalized by the amount of pka-apoA-I protein (from 
part A) versus the increasing amounts of apoA-I added.  The equilibrium binding constant (Kd) of 
recombinant pka-apoA-I was calculated from the saturation curve (from part C) using the graphing 
program GraphPad. 
 
 
To evaluate the recycling pathway further, increasing levels of native human apoA-I were 
added to compete with pka-apoA-I for cell entry.  Since human apoA-I contains no PKA-
tag, decreases in phosphorylation indicate that pka-apoA-I is specifically being blocked 
from cell entry.  Cells were [32P]-radiolabeled and a constant concentration of pka-apoA-I 
was maintained with varying amounts of competing human apoA-I added.  Media was 
collected after the incubation time and separated by gel (Fig. 9B).  Pka-apoA-I travels as 
a 31 kDa protein while un-tagged human apoA-I travels at its native size (28kDa) below 
it.  Results show that pka-apoA-I loses phosphorylation as the human apoA-I 
concentration is increased (Fig. 9A).  A control (Fig. 9A, 9B, lane1) was added to show 
that incubation of human apoA-I does not induce secretion of any unknown phospho-
proteins at the same size as pka-apoA-I.  Phosphorylation of pka-apoA-I was then plotted 
versus the competing human apoA-I concentrations to assess the level of competition 
between human and recombinant apoA-I (Fig. 9C).  Analysis of the inhibitor-response 
curve reveals that human apoA-I behaves similar to recombinant pka-apoA-I with 
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Ki ~1µM.  This implies that recombinant and human apoA-I are most likely competing 
for cell entry from the same receptor. 
 
               
Figure 9. Human apoA-I competes with recombinant pka-apoA-I for entry into the cell.  Recycling 
assays of pka-apoA-I were performed as described previously with increasing amounts of human apoA-I 
added.  A. Autoradiogram showing that human apoA-I competes with pka-apoA-I for entry and exit from 
the cell.  B. Coomassie gel with 10% of the well media loaded. Shows pka-apoA-I concentration constant 
and human apoA-I is increasing.  C. Graph of autoradiogram versus the human apoA-I concentrations in 
part B. GraphPad software was used to plot the log dose-response curve and calculate the Kd of inhibition 
(Ki) and IC50 of human apoA-I.  The Ki of 828nM (23 µg/mL) has 95% CI of 422 to 1625nM and the IC50 
of 45.9 µg/mL has 95% CI of 23.4 to 90.2 µg/mL.  
 
 
ii. Effect of ApoLp-III and Thrx on recycling of pka-ApoA-I. 
Since human apoA-I competed with pka-apoA-I for cell entry, experiments were 
designed to further test the specificity of the recycling receptor.  This was investigated by 
experiments designed to perform the apoA-I recycling assays in the presence of other 
types of proteins.  ApoLp-III was chosen to test whether the apoA-I receptor may have 
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affinity for other apolipoproteins.  Similar to apoA-I, it is mainly alpha helical and binds 
to the lipids of lipoparticles [151].  Thrx was also chosen as a generally unrelated protein 
to monitor the level of specificity needed to compete for recycling.  The coding regions 
of these proteins were cloned into plasmids such that the recombinant proteins contained 
a HIS-tag for purification as well as the PKA-recognition site tag similar to the pka-
apoA-I construct (Fig. 10).     
 
 
Figure 10.  ApoA-I, ApoLp-III and Thrx pka-tag recombinant protein constructs.  Sequence coding 
for mature apoLp-III and Thrx were cloned into plasmids such that the recombinant proteins would contain 
a N-terminal HIS-tag to facilitate purification and PKA-recognition site tag to enable use of the construct in 
recycling assays as described in Methods.  The recombinant proteins are diagrammed above to show the 
different coding regions. The open boxes represent the 6 histidine residue tag and the closed boxes 
represent the PKA recognition sequence RRASV. Intervening amino acid sequence between tags and 
protein sequence is represented by the thin gray bar and sequence coding for either ApoA-I, ApoLp-III or 
Thrx is represented by blue, orange or green boxes, respectively.  The dimensions of each region are 
proportional to number of amino acids such that relative (primary) sizes are visualized.  
 
 
Because all the recombinant proteins used for this study contain a pka-recognition site 
phosphorylation tag, the internalization of apoA-I as well as the other two proteins can be 
monitored (Fig. 10).  For the experiments, increasing amounts of either apoLp-III or Thrx 
were added simultaneously with apoA-I to [32P]-radiolabeled adipocytes.  Pka-apoA-I, 
which was shown previously to be internalized and re-secreted from adipocytes, can be 
added to culture media with or without the potential competitors, and the recycling 
monitored by analysis of the medium following the incubation time. 
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Figure 11.  The effect of apoLp-III and Thrx on apoA-I recycling.  Competition recycling assays of 
pka-apoA-I were performed as described previously (Methods section III.x) with increasing amounts of 
apoLp-III (3 or 6 nmol) or Thrx (3 or 6 nmol) or human apoA-I (as described previously) added to culture 
wells along with pka-apoA-I (1.5nmol).   A. Representative Coomassie-stained gel of media samples with 
arrows indicating location of pka-apoA-I, apoLp-III, Thrx or human apoA-I.  B. Autoradiogram of gel 
(from A) showing [32P]-phosphorylation of pka-recombinant proteins.  C. Average phosphorylation of pka-
recombinant proteins as determined by autoradiography of media gels (arbitrary units of densitometry).  
Bars represent the mean ± s.d. of two independent experiments for apoA-I:apoLp-III (n=5) and one 
experiment for apoA-I:Thrx (n=3) and human apoA-I.  The differences between pka-apoA-I densities of 
phosphorylation were found to be not significant by student’s t-test (p>0.05) for both apoLp-III and Thrx 
competition assays.   
 
 
As can be seen in figure 11, pka-apoA-I is recycled through adipocytes as expected 
(lanes 1, 6, 9) and although added with apoA-I to cells, the proteins apoLp-III and Thrx 
do not compete with apoA-I for cell entry (Fig. 11C).  In contrast, addition of human 
apoA-I resulted in competition with pka-apoA-I for recycling as determined previously 
(Fig. 9, 11).  
Interestingly, although apoLp-III and Thrx don’t reduce the pka-apoA-I internalization, 
they themselves are internalized and re-secreted but to what seems to be a much lower 
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degree than apoA-I (apoLp-III ~30 fold less and Thrx ~7.5 fold less relative to 
pka-apoA-I; Fig. 12C).  These results show that receptor-mediated apoA-I recycling has a 
higher specificity for apoA-I than other proteins (including some apolipoproteins).   
 
 
Figure 12.  Recycling of apoLp-III and Thrx compared to apoA-I in adipocytes.  Recycling assays of 
apoLp-III and Thrx were performed as described previously with increasing amounts of pka-apoLp-III (3 
or 6 nmol) or pka-Thrx (3 or 6 nmol) or pka-apoA-I (3 nmol) added alone to culture wells.   A. 
Representative Coomassie-stained gel of media samples (15% volume loaded) showing location of 
pka-apoA-I, pka-apoLp-III and pka-Thrx.  B. Autoradiogram of gel (from A) showing 
[32P]-phosphorylation of pka-recombinant proteins.  C. Average phosphorylation of pka-recombinant 
proteins as determined by autoradiography of media gels (arbitrary units of densitometry).  Bars represent 
the mean ± s.d. of two independent experiments for apoLp-III (n=5) and one experiment for Thrx (n=3).  
The differences between pka-tag phosphorylation of 3 and 6 nmol incubations of either apoLp-III or Thrx 
were found to be not significant by student’s t-test (p>0.05).   
 
 
iii. Inhibitors of ABCA1 (BFA) and SRBI (BLT1) do not inhibit apoA-I uptake and 
resecretion.   
Next the role that the receptors ABCA1 or SRBI may play in the lipidation of apoA-I was 
investigated through use of the inhibitors BFA and BLT1.  To examine the possibility 
that ABCA1 may be mediating both apoA-I cellular uptake and resecretion along with 
lipid efflux, BFA was used to block ABCA1 recycling and cell surface availability [31].  
As shown previously, BFA is also a strong inhibitor of ABCA1-mediated efflux to 
apoA-I (Chapter IV section v).  Additionally BLT1 was used to investigate SRBI as 
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another possible apoA-I recycling receptor.  BLT1 is known as a strong inhibitor of 
SRBI-mediated CL efflux to HDL [141], and previous work has also shown it to be 
capable of weak inhibition of ABCA1-mediated efflux in adipocytes 
(Chapter IV section v).   
For experiments, cells were [32P]-radiolabeled and the drugs BFA and BLT1 were 
allowed to pre-equilibrate before addition of pka-apoA-I.  Cell media was collected after 
the specified incubation times and pka-apoA-I purified using Ni-chromatography.  
Purified pka-apoA-I was run onto SDS gels (Fig. 13A) and exposed to film to visualize 
pka-apoA-I phosphorylation (Fig. 13B).  Because the lipolytic activity level of the cell 
regulates the PKA activity level and glycerol release into the media, medium glycerol 
levels are indicative of PKA activity levels.  Thus, to control for changes in PKA activity 
possibly induced by the drugs, an aliquot of media was used to measure glycerol levels.   
As can be seen in figure 13B, the phosphorylation is stronger in the samples with a 
40 minute medium incubation time.  Phosphorylation of these samples was analyzed by 
densitometry as mentioned previously and normalized by medium glycerol levels.  The 
results represent the levels of apoA-I recycling in the presence treatment with either BFA 
or BLT1 (Fig. 13C).   
Although the results show that apoA-I is retroendocytosed, these drugs, which were 
previously shown to inhibit apoA-I lipidation, have no inhibition on the uptake and re-
secretion of apoA-I.  This implies that apoA-I recycling involves a receptor besides those 
shown to be inhibited by BFA (ABCA1) and BLT1 (SRBI) and leads to the possibility 
that apoA-I recycling through adipocytes may be independent from its lipidation.  
Similarly, other studies have concluded that apoA-I internalization in macrophages may 
not significantly contribute to overall efflux levels and that only a low level of 
internalized apoA-I co-localizes with ABCA1 [119, 152].   
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Figure 13. Efflux drugs do not inhibit pka-apoA-I uptake and resecretion.  [32P]-prelabeled adipocytes 
were pre-equilibrated with BFA (10 µg/ml) or BLT1(10 µM) for 2h prior to incubation with 50 µg/mL 
pka-apoA-I.  The media was collected and analyzed for tag-phosphorylation and rate of glycerol release as 
described previously.  A. Coomassie gel showing pka-apoA-I purified per time point.  B. Autoradiogram of 
the dried gel (from part A) showing phosphorylation of purified apoA-I.  C. Graph of autoradiogram 
normalized by protein amount (from part A, 40’ samples) and medium glycerol rates.  Error bars represent 
the mean ± s.d., n=2. Sample’s were not significantly different as determined using the students t-test 
(p>0.05). 
 
 
iv. Antibody to ATP synthase beta subunit blocks cell entry and exit of apoA-I.  
The above studies have shown that apoA-I recycling involves a pathway separate from 
those involved in ABCA1-mediated efflux.  Therefore, claims that cell surface ATP 
synthase acts as an apoA-I receptor were investigated.   
Ectopically expressed ATP synthase F1 subunit β (ATPase β) was first discovered to bind 
apoA-I when Martinez et al. used immobilized apoA-I to probe solubilized membrane 
proteins [150].  Subunits of the traditionally mitochondrial protein have been shown to be 
present on the cell surface of hepatocytes, lymphocytes, endothelial cells and adipocytes 
but not erythrocytes nor Chinese hamster ovary cells [150, 153-155].  Although studies 
are lacking for all these cell types, the complete ATPase complex with both the 
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membrane-embedded F0 and the soluble F1 (containing α,β,γ,δ,ε subunits) subdomains 
has been shown to be present in isolated rat hepatocytes [156].  Ectopically expressed 
ATPase has been shown to exhibit ATP synthesis and hydrolysis activities in both 
hepatocytes and endothelial cells [156-158].  Furthermore, antibodies to α and β subunits 
of the F1 subdomain have been shown to inhibit the synthase/hydrolase activities of 
ATPase [156-158].    
Because cell surface expressed ATPase β had been shown to bind apoA-I [150], the 
effect that β subunit antibodies had on apoA-I uptake and re-secretion from adipocytes 
was investigated.  For this experiment, [32P]-prelabeled adipocytes were pre-incubated 
with increasing amounts of anti-ATPase β prior to the experiment.  Two monoclonal 
antibodies to the beta subunit of ATP synthase (clones 3E8 and 3D5) were chosen to 
study the effect on apoA-I uptake.  After antibody pre-incubation, apoA-I was added to 
the experimental medium and the media removed after the incubation period. Cell entry 
of apoA-I and exit back into the cell media was monitored by the phosphorylation of the 
pka-tag.  ApoA-I was purified from the media using Ni-affinity chromatography then 
analyzed by SDS-PAGE and autoradiography as shown in figure 14A and 14B 
respectively.   
The results show that apoA-I uptake and re-secretion is accompanied by phosphorylation 
of the construct’s pka-tag (lane 1, Fig. 14B) and that this phosphorylation is blocked by 
increasing amounts of anti-ATPase β clone 3D5 (lane 2-7, Fig. 14B).  Although anti-
ATPase β clone 3D5 successfully blocked apoA-I recycling, the other clone (3E8) 
investigated did not have a significant effect on apoA-I phosphorylation levels (Fig. 14C, 
p>0.05).  To further classify the inhibition by clone 3D5, phosphorylation of pka-apoA-I 
was plotted versus antibody dose (Fig. 14D).  The results indicate that the level of 
recycled apoA-I rapidly falls upon incubation with antibody until reaching a low at 
approximately 35% of maximum phosphorylation.  This is comparable to the inhibition 
of endothelial cell-surface ATP synthase activities observed in a previous study by 
binding of a monoclonal antibody (Mab3D5) to the domains near the active site of the 
beta subunit [158].  The log dose-response of the inhibition was plotted and the curve was 
used to calculate an IC50 for the antibody clone 3D5 at ~10.6 µg/mL (95% CI of 4.722 to 
23.88 µg/mL).  PKA activity levels were also checked through measurement of glycerol 
release into the media (Fig. 14E).  The glycerol levels showed no significant change, 
demonstrating that changes in pka-apoA-I phosphorylation were not due to changes in 
intracellular PKA activity (Fig. 14E, p>0.05). 
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Figure 14. The effect of antibody to ATP synthase (β subunit) on cellular uptake and release of 
pka-apoA-I.   
Recycling assays of pka-apoA-I were performed as described previously with increasing amounts of 
antibody to ATPase β (either monoclonal 3D5 or 3E8) allowed to pre-incubate 1 h prior to addition of 
pka-apoA-I (40 µg/mL).  The media was collected and analyzed to detect tag pka site phosphorylation as 
described previously.  A. Representative Coomassie blue stained gel and B. autoradiogram displaying 
phosphorylation of purified pka-apoA-I protein.  C. Protein and phosphorylation amounts (such as from A 
and B) were quantified and plotted by the amount of antibody added.  Error bars represent standard error of 
the mean from two independent experiments per clone with at least duplicates per sample.  Significance of 
differences was determined from 0 to 8 µg/mL of antibody with student’s t-test and using one-way 
ANOVA with post tests for linear trend (3D5, p<0.0001 and 3E8, p>0.05) using GraphPad software.  D. 
Phosphorylation of pka-apoA-I released into media (as determined by densitometry of gel and 
autoradiogram) was plotted versus antibody dose.  E. Glycerol released into media was measured to 
monitor lipolytic and PKA activity levels.  Error bars in D and E represent mean ± s.d. with n=2-6 from 2 
independent experiments. 
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v. Antibody to ATP synthase beta subunit does not affect apoA-I dependent cholesterol 
efflux levels.    
Because previous studies were able to pharmacologically uncouple apoA-I recycling 
from apoA-I lipidation using BFA, cholesterol efflux was measured to confirm that 
antibody blocking of pka-apoA-I cellular entry has no effect on cholesterol efflux to 
apoA-I.  Cholesterol efflux experiments involve [3H]-cholesterol pre-labeling for 
24 hours in media containing a decreased amount of serum compared to the previous 
[32P]-labeling experiments.  Previous literature has shown that cell medium serum levels 
influence ATPase ectopic cell surface expression in HepG2 hepatocytes and the human T 
cell line CEM [159, 160].  Under serum starvation conditions ATP synthase surface 
expression is induced [159, 160].  Because surface levels of ATPase are influenced by 
medium serum concentrations, a control [32P]-labeling recycling assay was performed in 
the same manor and media conditions as [3H]-cholesterol efflux experiments to ensure 
the significant antibody blocking of pka-apoA-I cell entry. 
As can be seen in figure 15, the cholesterol efflux rate to apoA-I is unchanged even when 
co-incubated with anti-ATPase β, which is shown to block pka-apoA-I cell entry under 
similar experimental conditions (Fig. 15A, 15B).  It should be noted that, although 60 µg 
of antibody significantly blocks the cellular uptake of pka-apoA-I, the percent inhibition 
is only approximately 40%, whereas under previous experimental conditions recycling 
inhibition was at approximately 60%.  This difference is most likely due to changes in the 
labeling-medium conditions of the different experiments which may affect cell surface 
expression of ATPase β.  Indeed, studies have shown that medium levels of cholesterol 
and serum concentrations dramatically affect the cell surface expression of ATP synthase 
and thus may have varying affects on our pka-apoA-I recycling assays [159, 161].  This 
highlights the importance of monitoring cell entry in the same experiment and manor as 
the cellular cholesterol efflux measurements. 
However, despite this 40% inhibition, cholesterol efflux remains unaffected.  These 
results are in line with other works showing that ATPase activity when blocked by 
inhibition factor 1 (IF1) shows no effect on efflux to apoA-I, and moreover shows that the 
apoA-I cell entry and release is unrelated to the overall lipidation of apoA-I [150].   
 
 
 45 
 
 
Figure 15. Effect of anti-ATPase β on ApoA-I-dependent cholesterol efflux. 3T3 L-1 adipocytes were 
radiolabeled with [3H]-cholesterol as mentioned in methods and pre-equilibrated 1 h prior to pka-apoA-I 
addition with or without 60 µg anti-ATPase β clone 3D5.  A. Efflux assay media was collected at indicated 
time points and cholesterol efflux rate calculated from the time courses of the CL efflux and represented in 
B.  B. For ‘Recycling’ data, 1 h media was collected and apoA-I purified.  Protein concentration was 
determined as mentioned in methods (III.xv).  The media was collected and analyzed for tag-
phosphorylation as described previously.   Bars in part A represent mean  ± s.d. of n=4 and solid bars in 
part B (for efflux rate) represent the standard error of the slope from part A and the open bars (for recycling 
assays) represent the mean ± s.d. of n=4.  
 
 
vi. Antibody to ATP synthase beta subunit does not affect apoA-I-dependent 
phospholipid efflux levels.   
The mechanism of apoA-I lipidation involves both CL and PL loading of apoA-I, but it is 
unclear if this occurs simultaneously or in steps.  Although our results have shown CL 
efflux to be independent from apoA-I recycling, PL efflux was also examined to clearly 
define the relationship of apoA-I recycling and HDL formation.   
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The effect on the level of PL efflux was investigated by adding increasing amounts of 
anti-ATPase β to cells.  Cells were prepared by the radiolabeling and antibody addition as 
described previously.  After apoA-I incubation, experimental media was collected and 
Ni-affinity purified to obtain effluxed lipids associated to apoA-I.  The lipids were 
extracted by modified Folch to remove the free phosphate and protein fractions from the 
organic phase containing radiolabeled phospholipids.  Scintillation counting of the 
phospholipids were normalized by apoA-I UV absorbance levels at 280nm and plotted by 
the amounts of antibody added to the media (Fig. 16).  The results show that 
phospholipid efflux levels associated to apoA-I are not significantly affected by antibody 
levels (Fig. 16, student’s t-test p>0.05).   
 
 
Figure 16. Effect of anti-ATPase β on ApoA-I-dependent phospholipid efflux. [32P]-prelabeled 
adipocytes were pre-equilibrated with anti-ATPase β clone 3D5 at the indicated concentrations for 1 h prior 
to pka-apoA-I (40 µg/mL) addition.  ApoA-I was then purified from the experimental medium and protein 
concentration was determined by UV280nm.  Phospholipids were then extracted (as described in Methods 
III.xiv) and [32P]-labeled phospholipids measured by scintillation counting and normalized by protein UV 
absorbance levels.  Error bars represent mean ± s.d. of n=2-6 from two independent experiments. 
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CHAPTER VI 
 
 
DISCUSSION 
 
i.  Characterization of apoA-I dependent lipid efflux from adipocytes. 
 
As the largest storage site of free cholesterol in the body, adipocytes have the potential to 
influence circulating HDL [59, 60].  Studies have shown correlations in obesity and 
altered component lipid ratios of circulating HDL [63-65].  Upper body fat accumulation 
is associated with lower HDL levels and increased CHD risk [64].  This suggests that 
lipid efflux from adipocytes has the potential to significantly alter overall HDL levels and 
compositions.  ApoA-I has been demonstrated to utilize ABCA1 for cholesterol and 
phospholipid efflux from other cell types but the process had not been well characterized 
in adipocytes until now.  These studies which have furthered the characterization of both 
CL and PL apoA-I dependent efflux from adipocytes highlight the ability of adipocytes to 
contribute to the HDL population.  
 
Quantification of lipid efflux 
The studies presented above have compared the molar rates of lipid efflux to apoA-I from 
both adipocytes and macrophages.  The radiolabel pulse-chase efflux assay is a common 
assay to assess the efflux potential of cells in culture, acceptors and transporters.  The 
efflux data of these assays are commonly expressed as the percent of label (in 
experimental media) out of the total cellular label.  Although this is adequate for 
comparison of treatments or differences in assay conditions, it is inadequate for 
comparisons across cell types due to variance in lipid content.  In order to evaluate a 
cell’s potential contribution to HDL, the molar content of the lipids effluxed must be 
established.  Our results showed that adipocytes efflux cholesterol at similar molar rates 
as macrophages but at lower rates than cAMP-treated macrophages.  Conversely, the rate
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of phospholipid efflux from adipocytes was higher compared to macrophages.  This 
resulted in a higher ratio of CL:PL efflux from macrophages (~4) compared to adipocytes 
(~2) but in a similar ratio for cAMP-treated macrophages compared to adipocytes.  This 
means that adipocytes release HDL particles that are CL-poor compared to control 
macrophages, are the same as cAMP-treated macrophages and are CL-rich compared to 
smooth muscle cells and some fibroblasts [16, 162].  Because cAMP is believed to 
hyperactivate lipid efflux to apoA-I via the ABCA1-mediated efflux pathway and the 
stoichiometry of efflux from adipocytes matches that of cAMP-treated macrophages, 
these results support a role for ABCA1 in the apoA-I dependent lipid efflux from 
adipocytes.  
 
Homogenate lipid compositions  
The CL and PL lipid content determination of homogenates confirmed that adipocytes 
contain higher levels of CL as reflected in the higher CL per PL compared to macrophage 
homogenates.  These lipid measurements were similar to previous literature measuring 
adipocyte tissue lipid compositions as well as previous literature on J774 macrophages 
[59, 131].  Other works have also identified changes in homogenate lipid compositions 
after treatment with cAMP or LXR-agonists [163, 164].  Interestingly, 8-Bromo-cAMP 
treatments in those studies resulted in CL accumulation in epithelial cells, while use of a 
LXR-agonist resulted in lower CL accumulation in HepG2 cells.  Contrary to these 
reports, our studies of treatment with either cAMP or GW3965 resulted in a slight 
decrease in both CL and PL homogenate lipid levels which was determined to be 
insignificant by student’s t-test (data not shown, p>0.05).   This difference is most likely 
due to differences in assay conditions including medium compositions and longer 
incubation periods of cells of those previous studies with the drugs.     
 
Role of ABCA1 
Results of the efflux assay studies in combination with western blotting have provided 
evidence that ABCA1 protein levels are correlated to apoA-I dependent lipid efflux.  
These assays showed first, that ABCA1 is expressed in adipocytes at similar levels as the 
expression level in macrophages.  And secondly, they show that the LXR-agonist 
GW3965 increased both ABCA1 protein levels (2 fold) and efflux (1.5 fold) from 
adipocytes.  ABCA1 induction in macrophages by cAMP resulted in a 4.7 fold increase 
in ABCA1 protein levels with a 2.3 fold increase in CL efflux.   
Additionally, it was shown that CL efflux to apoA-I from adipocytes occurs at the same 
rate as from macrophages when the rates are normalized by the amount of ABCA1 
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protein expressed in cells.  These results implicate ABCA1 to be in control of apoA-I 
dependent lipid efflux from both adipocytes and macrophages.   
Surprisingly, the rate of efflux per ABCA1 protein, or efficiency of efflux, was higher for 
untreated cells compared to the ABCA1-induced cells.  This could be explained in two 
different ways.  One possibility is that there is some factor responsible for a low level of 
apoA-I-inducible cholesterol efflux that is downstream or independent of 
ABCA1-mediated efflux.  This would result in higher efficiency of efflux per ABCA1 in 
control cells if this other factor is not increased in the treated cells.  Therefore this 
efficiency would not be seen in treated cells because it is overcast by the increased levels 
of ABCA1-mediated efflux.  This factor could be another protein that may facilitate a 
higher efficiency of efflux through or supplemental to the ABCA1 pathway.  The 
concentration or activity of this other factor is probably regulated similar to the basal 
regulation of ABCA1, since there is a similar level of efficiency between adipocytes and 
macrophages per expression of ABCA1.  However, because this higher efficiency of 
efflux is not seen in the experimentally treated states, it could not be a protein 
upregulated by cAMP or LXR.  This means that while treatment of cells with either 
cAMP or LXR-agonists increases ABCA1 levels, it does not increase another unknown 
component of the efflux pathway which would allow for the more efficient efflux per 
ABCA1 level seen in the control cells.  Potential candidates include SRBI and ABCG1, 
which are both known to efflux CL to ABCA1-formed HDL [67, 81].  Through studies in 
various cell types, LXR is known to upregulate ABCG1 but not SRBI and conversely, 
cAMP is known to upregulate SRBI but not ABCG1 [165-169].  Because studies in 
adipocytes are lacking, it is unknown how these drugs may affect these non-ABCA1 
transporters of adipocytes.  But if similarly regulated, it is possible that the LXR- or 
cAMP-treatment would result in less SRBI or ABCG1 per ABCA1 compared to the 
uninduced state.  Thus, ABCG1, SRBI or some other unknown protein factor may 
influence the efficiency of the ABCA1 efflux pathway.  
Another possibility is that the level of efflux efficiency could be due to the levels of 
functionally active ABCA1 compared to overall homogenate levels of ABCA1.  Studies 
show that the cell surface expression levels of ABCA1 are linked to its ability to mediate 
apoA-I-dependent lipid efflux [43].  In control cells where ABCA1 levels are lower, 
higher cell-surface localization would help maintain a higher efficiency efflux level.  
However, in induced cells where ABCA1 levels are upregulated, ABCA1 may be located 
not only on the cell surface but also in processing or en route.  This would result in 
division of the efflux by a higher ABCA1 concentration than that which is actually 
responsible for it and would seemingly result in a lower efficiency.  Although this is 
possible, this is less likely since the non-active ABCA1 levels would have to be the same 
for both the LXR-treatments in adipocytes and cAMP-treatments in macrophages since 
the efficiency is similarly repressed. 
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Despite the different possibilities, the ratios of CL efflux per ABCA1 protein levels 
remained constant when comparing the control cell-types to each other or the treated cell-
types to each other.  This again suggests that ABCA1 is the major transporter involved in 
lipid efflux to apoA-I from adipocytes in both basal and LXR activated states.  
To further investigate the role of ABCA1 in apoA-I dependent lipid efflux from 
adipocytes, the inhibition effects of the ABCA1-targeting drugs GLYB and BFA on lipid 
efflux from both adipocytes and macrophages were compared.  The results showed that 
GLYB and BFA inhibit apoA-I dependent efflux from adipocytes at similar levels as 
those seen in macrophages.  Additionally, this work represents the first to study the effect 
of the drugs BLT1 and BLT4 not only on cholesterol efflux inhibition but also 
phospholipid efflux inhibition.  BLT1 only slightly inhibited PL efflux to apoA-I, which 
is expected since BLT1 targets SRBI-mediated lipid efflux to HDL and not 
ABCA1-mediated apoA-I dependent efflux.  BLT1 also partially inhibited CL efflux, 
which can be explained by reasoning that BLT1 may be blocking SRBI-mediated efflux 
to lipoparticles formed after apoA-I addition to the cells within the time frame of the 
assays.  However, in the case of GLYB/BFA, PL efflux inhibition seems to be the same 
or slightly higher (ns GLYB CL-PL; ** p=0.0012 BFA CL-PL) than the inhibition of CL 
efflux.  If real, this difference could also be explained by downstream CL-enrichment of 
nascent HDL particles, such as SRBI/ABCG1-mediated efflux or diffusion.  Different 
from both these cases however, is inhibition by BLT4.  BLT4 is unique in that it inhibits 
not only ABCA1-mediated efflux of lipids to apoA-I but also SRBI-mediated efflux to 
HDL.  Contrary to previous reports in ABCA1-overexpressed HEK293 cells, our assays 
in adipocytes show BLT4 does not inhibit CL efflux to the same degree as GLYB or BFA 
but instead is slightly lower [142].  Since BLT4 has been shown to block ABCA1, it was 
also surprising that BLT4 did not inhibit PL efflux as strongly as it did CL efflux.  
However, this difference can be explained by BLT4’s ability to also inhibit the possible 
downstream HDL CL-enrichment by SRBI.  This unique study on the effects of BLT1 
and BLT4 on both CL and PL efflux to apoA-I and comparison to GLYB/BFA provides 
support for the idea that nascent HDL particles may be further CL-enriched.  The degree 
to which this CL-enrichment occurs may vary by cell-type and requires further studies to 
understand the effect on circulating HDL compositions and functionality.  
 
ii.  ApoA-I recycling in adipocytes. 
Despite many recent studies, the relationship of apoA-I recycling to efflux and the 
localization of apoA-I lipidation is still highly controversial [25, 26].  The works 
presented here show that apoA-I uptake and resecretion is a specific receptor-mediated 
process that can be blocked by an antibody to the β subunit of ATPase.  Definitively, 
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blocking of apoA-I recycling was shown to have no significant effect on phospholipid or 
cholesterol efflux to apoA-I acceptors.  
 
Cell surface ATPase subunit β as an apoA-I receptor 
ATPase is expressed ectopically on the cell surface in several cell lines [150, 153-155].  
It is also functionally active on the cell surface although separate studies have shown 
differences in either hydrolase or synthesis activities [150, 156-158, 170].  Consistent 
with apoA-I binding to cell surface ATPase, ATPase subunit β has been shown to bind to 
alpha helical proteins such as vasoconstrictor coupling factor 6, the inhibitory protein 
(IF1) and apoE [171-173] as well as to the proteolytic fragment angiostatin [154].  
Because ATPase β has been shown to bind these proteins, it seems possible that it may 
bind other apolipoproteins which share the apoA-I alpha helical nature.  But, these 
studies have shown that the apoA-I recycling is not inhibited by addition of competing 
amounts of apoLp-III.  This implies that the specific interaction of apoA-I with cell 
surface ATPase governs apoA-I recycling in adipocytes.  Whether apoE, which was 
shown to bind to solubilized ATPase, binds to cell surface ATPase requires further study.   
 
Role of apoA-I-ATPase β interaction 
Studies investigating the function of the apoA-I interaction with ATPase have indicated 
that the interaction leads to a decrease in cytosolic lipid droplet (LD) accumulation in 
adipocytes [174].  Interestingly, those studies also showed that antibodies to the β subunit 
mimic the apoA-I interaction which caused the decreases in cytosolic LD accumulation.  
In the present studies, apoA-I was blocked from cell entry and resecretion by 
anti-ATPase β, but lipid efflux to apoA-I receptors remained un-modified.  This led to the 
conclusion that apoA-I uptake and re-secretion is not involved in lipid efflux.  However, 
in light of the previous activity studies where the apoA-I binding response is mimicked 
and not blocked by antibody, apoA-I binding to ATP synthase may result in signaling 
which is not blocked by the antibody in our recycling assays.  This signaling would have 
to be independent of recycling since our assays show that apoA-I cell entry and exit is 
blocked by anti-ATPase β, but other possible downstream signals elicited by apoA-I 
binding would not be ruled out.  
One the other hand, apoA-I has been shown to stimulate hydrolase activity in hepatocytes 
[150] while antibodies have been shown to inhibit both ATP synthesis and hydrolysis in 
several cell types [150, 156-158, 170, 174].  ATPase hydrolase activity has been linked to 
HDL endocytosis via a non-SRBI receptor in hepatocytes [150].  Those studies have 
proposed that ATPase-mediated ADP production leads to the activation of the G-protein 
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coupled receptor P2Y13 on the hepatocyte surface which modulates HDL endocytosis 
[175, 176].  ApoA-I stimulation of this pathway, through ADP production, was inhibited 
by antibodies to the ATPase subunit β [150].  Research in adipocytes is limited but some 
studies have proposed that HDL endocytosis in adipocytes may be SRBI-related instead 
of ATPase mediated [155, 177].  Contrarily, the above works show that the SRBI 
inhibitor BLT-1 has no significant affect on pka-apoA-I uptake and re-secretion.  The 
above studies on this novel pathway are preliminary and need further work to establish 
the role of the apoA-I-ATPase interaction in adipocytes.  Furthermore results show only 
~65% inhibition of pka-apoA-I phosphorylation indicating that other pathways, not 
involving cell surface ATPase, may also be involved in apoA-I recycling.  As such, 
blocking of apoA-I-ATPase mediated recycling would not affect those other possible 
pathways.  This would account for studies linking apoA-I recycling to the ABCA1 
endocytic pathway [117, 120, 178].   
Overall these studies have shown that the apoA-I-ATPase interaction functions in 
adipocyte apoA-I recycling and further that this apoA-I uptake does not play a major role 
in lipid efflux to apoA-I. 
 
iii.   Physiological Relevance 
The adipocyte contribution to overall HDL levels was found to be at the same level of 
contribution as J774 macrophages in cell culture.  Because this is a cell by cell 
comparison, we would expect the influence of adipocytes on HDL in circulation to be 
much larger than the contribution of macrophages since the adipocytes far outnumber 
macrophages.  Also, the characterization of HDL lipid compositions revealed that the 
lipoparticles formed from the apoA-I dependent lipid efflux from adipocytes were CL-
poor compared to control macrophages.  This means that this CL-poor (relative to 
macrophages) HDL particle will be a more efficient acceptor of CL efflux from cells.  
Therefore, because HDL is dynamically remodeled and apoA-I available to induce lipid 
efflux from adipocytes, adipose tissue is expected to be a significant regulator of the 
HDL compositions in circulation.  Also, since the ability of HDL to accept CL from CL-
loaded foam cells is believed to be responsible for the atheroprotective nature HDL, the 
HDL biogenesis from adipocytes can only be characterized to aid this process.    
It has also been shown by works in this laboratory that CL efflux increases from 
adipocytes to HDL acceptors in the lipolytic state [27].   The cellular source of this CL 
efflux was not the plasma membrane and the lipolytic mobilization involved BFA-
sensitive vesicular transport.  This study showed that adipocytes do have the metabolic 
potential to affect circulating cholesterol levels.   
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Although those works had revealed the importance metabolic state on adipocyte CL 
efflux to HDL, the influence of adipocytes on HDL biogenesis had not been characterized 
until now.  Due to the prevalence and convergence of obesity and heart disease the 
continued study of adipocyte influence on these processes are an important public health 
priority.  The studies presented above have laid the groundwork for such studies by 
characterizing the HDL compositions, contributions and mechanisms of apoA-I 
dependent lipid efflux from adipocytes.  As such, these studies are crucial cornerstones 
for future studies on the influence of metabolic states on lipid efflux from adipocytes.  
 
iv.   Concluding Remarks 
The studies presented here have sought to characterize the apoA-I dependent lipid efflux 
of adipocytes.  The rates of CL and PL efflux from adipocytes upon apoA-I incubation 
were determined and show that lipid efflux from adipocytes is induced by apoA-I at a 
similar rate as from macrophages.  The CL to PL stoichiometric efflux ratio of adipocytes 
was also similar to the lipid efflux ratio seen in macrophages, implicating by comparison 
the ABCA1-mediated pathway in adipocytes.   
To investigate the role of ABCA1, the apoA-I dependent lipid efflux levels were 
normalized by cellular ABCA1 protein content.  This ‘efficiency’ of lipid efflux was 
analyzed in both adipocytes and macrophages and the comparison showed that apoA-I 
induces lipid efflux at the same rate per ABCA1 protein from adipocytes as from 
macrophages.  To further test the role of ABCA1, the drugs GLYB, BFA and BLT4, 
which target the ABCA1 efflux pathway, were used to analyze apoA-I-dependent efflux 
from adipocytes.  The results show patterns of inhibition expected for apoA-I induction 
of efflux via an ABCA1-mediated pathway.  Collectively, the studies provide strong 
support for ABCA1 as the main transporter involved in lipid efflux from adipocytes to 
apoA-I. 
Investigation of apoA-I internalization through use of pka-tagged apoA-I revealed that 
apoA-I is recycled in adipocytes [121].  pka-ApoA-I recycling was found to be a specific 
process that human apoA-I could compete with, but not apoLp-III or Thrx. The recycling 
was also saturatable and this lead to the proposition of receptor involvement in apoA-I 
cellular uptake and re-secretion.  First, ABCA1 was tested as the possible recycling 
receptor but the ABCA1-inhibitor BFA failed to block apoA-I recycling.  Similarly the 
drug BLT1, which blocks SRBI-mediated CL flux to HDL, also had no effect on apoA-I 
recycling.  The next receptor to be tested was the ectopically expressed cell surface ATP 
synthase subunit β.  Surprisingly, the phosphorylation of pka-apoA-I was blocked by use 
of a monoclonal antibody to ATPase β.   
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Finally, the ability of anti-ATPase β to block apoA-I internalization was used as a tool to 
directly analyze the relationship of apoA-I recycling to lipidation.  CL and PL efflux 
assays carried out in the presence of anti-ATPase β showed that lipid efflux to apoA-I 
remained unaffected by antibody blocking of apoA-I recycling.  This is the first direct 
study to show that apoA-I recycling is unrelated to apoA-I lipidation. 
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Findings and Conclusions:   
These studies have sought to characterize the apoA-I dependent lipid efflux of 
adipocytes.  The rates of CL and PL efflux from adipocytes upon apoA-I incubation were 
determined and show that lipid efflux from adipocytes is induced by apoA-I at a similar 
rate as from macrophages.  The CL to PL stoichiometric efflux ratio of adipocytes was 
also similar to the lipid efflux ratio seen in cAMP-treated macrophages, implicating by 
comparison the ABCA1-mediated pathway in adipocytes.   
The ‘efficiency’ of apoA-I dependent lipid efflux, that is, lipid efflux normalized by 
ABCA1 cellular protein content, was found to be the same in both adipocytes and 
macrophages.  To further test the role of ABCA1, the drugs GLYB, BFA and BLT4, 
which target the ABCA1 efflux pathway, were used to analyze apoA-I-dependent efflux 
from adipocytes.  The results show patterns of inhibition expected for apoA-I induction 
of efflux via an ABCA1-mediated pathway.  Collectively, the studies provide strong 
support for ABCA1 as the main transporter involved in lipid efflux from adipocytes to 
apoA-I. 
Investigation of apoA-I internalization through use of pka-tagged apoA-I revealed that 
apoA-I is recycled in adipocytes.  PKA-ApoA-I recycling was found to be a specific 
process that human apoA-I could compete with, but not apoLp-III or Thrx. The recycling 
was also saturatable and this lead to the proposition of receptor involvement in apoA-I 
cellular uptake and re-secretion.  To investigate this, ABCA1 was tested as a potential 
recycling receptor but the ABCA1-inhibitor BFA failed to block apoA-I recycling.  
Similarly the drug BLT1, which blocks SRBI-mediated CL flux to HDL, also had no 
effect on apoA-I recycling.  The next receptor to be tested was the ectopically expressed 
cell surface ATP synthase subunit β.  Surprisingly, the phosphorylation of pka-apoA-I 
was blocked by use of a monoclonal antibody to ATPase β.   
Finally, the ability of anti-ATPase β to block apoA-I internalization was used as a tool to 
directly analyze the relationship of apoA-I recycling to lipidation.  CL and PL efflux 
assays carried out in the presence of anti-ATPase β showed that lipid efflux to apoA-I 
remained unaffected by antibody blocking of apoA-I recycling.  This is the first direct 
study to show that apoA-I recycling is unrelated to apoA-I lipidation. 
 
 
